BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806. [PMID: 18772397 DOI: 10.1126/science.1164368] [Cited by in Crossref: 2682] [Cited by in F6Publishing: 2443] [Article Influence: 191.6] [Reference Citation Analysis]
Number Citing Articles
1 Hanoun N, Gayral M, Pointreau A, Buscail L, Cordelier P. Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. Hum Gene Ther. 2016;27:184-192. [PMID: 26731312 DOI: 10.1089/hum.2015.151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
2 Nobusawa S, Lachuer J, Wierinckx A, Kim YH, Huang J, Legras C, Kleihues P, Ohgaki H. Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol 2010;20:936-44. [PMID: 20406234 DOI: 10.1111/j.1750-3639.2010.00395.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 35] [Article Influence: 0.6] [Reference Citation Analysis]
3 Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546-1558. [PMID: 23539594 DOI: 10.1126/science.1235122] [Cited by in Crossref: 4552] [Cited by in F6Publishing: 3999] [Article Influence: 505.8] [Reference Citation Analysis]
4 Kang G, Hwang WC, Do IG, Wang K, Kang SY, Lee J, Park SH, Park JO, Kang WK, Jang J, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Kim MJ, Kim S, Park CK, Kim KM. Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. PLoS One 2013;8:e82770. [PMID: 24376576 DOI: 10.1371/journal.pone.0082770] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
5 Johnson B, Vanderwalde A, Javadi N, Feldman R, Reddy SB. Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy. J Gastrointest Oncol 2016;7:E6-E12. [PMID: 27034805 DOI: 10.3978/j.issn.2078-6891.2015.091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Antoniou G, Kountourakis P, Papadimitriou K, Vassiliou V, Papamichael D. Adjuvant therapy for resectable pancreatic adenocarcinoma: Review of the current treatment approaches and future directions. Cancer Treatment Reviews 2014;40:78-85. [DOI: 10.1016/j.ctrv.2013.05.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
7 Smith SJ, Li CM, Lingeman RG, Hickey RJ, Liu Y, Malkas LH, Raoof M. Molecular Targeting of Cancer-Associated PCNA Interactions in Pancreatic Ductal Adenocarcinoma Using a Cell-Penetrating Peptide. Mol Ther Oncolytics 2020;17:250-6. [PMID: 32368614 DOI: 10.1016/j.omto.2020.03.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Li H, Zhou W, Li L, Wu J, Liu X, Zhao L, Jia L, Sun Y. Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine. Neoplasia 2017;19:509-18. [PMID: 28535453 DOI: 10.1016/j.neo.2017.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
9 Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 2009;13:339-62. [PMID: 19236156 DOI: 10.1517/14712590902735795] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
10 [DOI: 10.1101/2020.08.23.263160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Guerra C, Barbacid M. Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol 2013;7:232-47. [PMID: 23506980 DOI: 10.1016/j.molonc.2013.02.002] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 11.3] [Reference Citation Analysis]
12 Xiang JF, Wang WQ, Liu L, Xu HX, Wu CT, Yang JX, Qi ZH, Wang YQ, Xu J, Liu C, Long J, Ni QX, Li M, Yu XJ. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/mL. Sci Rep 2016;6:19222. [PMID: 26753987 DOI: 10.1038/srep19222] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
13 Lowery MA, O'reilly EM. Novel Therapeutics for Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America 2015;29:777-87. [DOI: 10.1016/j.hoc.2015.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
14 Masetti M, Acquaviva G, Visani M, Tallini G, Fornelli A, Ragazzi M, Vasuri F, Grifoni D, Di Giacomo S, Fiorino S, Lombardi R, Tuminati D, Ravaioli M, Fabbri C, Bacchi-Reggiani ML, Pession A, Jovine E, de Biase D. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Cancer Biomark. 2018;21:323-334. [PMID: 29103024 DOI: 10.3233/cbm-170464] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
15 Dodhiawala PB, Khurana N, Zhang D, Cheng Y, Li L, Wei Q, Seehra K, Jiang H, Grierson PM, Wang-Gillam A, Lim KH. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations. J Clin Invest. 2020;130:4771-4790. [PMID: 32573499 DOI: 10.1172/jci137660] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
16 Cho YR, Lee JH, Kim JH, Lee SY, Yoo S, Jung MK, Kim SJ, Yoo HJ, Pack CG, Rho JK, Son J. Matrine suppresses KRAS-driven pancreatic cancer growth by inhibiting autophagy-mediated energy metabolism. Mol Oncol 2018;12:1203-15. [PMID: 29791786 DOI: 10.1002/1878-0261.12324] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
17 Orozco CA, Martinez-Bosch N, Guerrero PE, Vinaixa J, Dalotto-Moreno T, Iglesias M, Moreno M, Djurec M, Poirier F, Gabius HJ, Fernandez-Zapico ME, Hwang RF, Guerra C, Rabinovich GA, Navarro P. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A 2018;115:E3769-78. [PMID: 29615514 DOI: 10.1073/pnas.1722434115] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 12.5] [Reference Citation Analysis]
18 Vincent DF, Yan KP, Treilleux I, Gay F, Arfi V, Kaniewski B, Marie JC, Lepinasse F, Martel S, Goddard-Leon S. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet. 2009;5:e1000575. [PMID: 19629168 DOI: 10.1371/journal.pgen.1000575.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Nones K, Waddell N, Song S, Patch AM, Miller D, Johns A, Wu J, Kassahn KS, Wood D, Bailey P. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer. 2014;135:1110-1118. [PMID: 24500968 DOI: 10.1002/ijc.28765] [Cited by in Crossref: 129] [Cited by in F6Publishing: 111] [Article Influence: 16.1] [Reference Citation Analysis]
20 Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL, Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10-22. [PMID: 26851397 DOI: 10.1016/j.ejca.2015.12.026] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 14.2] [Reference Citation Analysis]
21 Maenhaut C, Dumont JE, Roger PP, van Staveren WC. Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis. Carcinogenesis. 2010;31:149-158. [PMID: 19858069 DOI: 10.1093/carcin/bgp259] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.5] [Reference Citation Analysis]
22 Conradt L, Godl K, Schaab C, Tebbe A, Eser S, Diersch S, Michalski CW, Kleeff J, Schnieke A, Schmid RM, Saur D, Schneider G. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. Neoplasia 2011;13:1026-34. [PMID: 22131878 DOI: 10.1593/neo.111016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
23 Chen Z, Hu J, Ying S, Xu A. Dual roles of SAMHD1 in tumor development and chemoresistance to anticancer drugs. Oncol Lett 2021;21:451. [PMID: 33907561 DOI: 10.3892/ol.2021.12712] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11:621-632. [PMID: 20683470 DOI: 10.1038/nrm2952] [Cited by in Crossref: 1547] [Cited by in F6Publishing: 1509] [Article Influence: 128.9] [Reference Citation Analysis]
25 Zaravinos A. The Regulatory Role of MicroRNAs in EMT and Cancer. J Oncol. 2015;2015:865816. [PMID: 25883654 DOI: 10.1155/2015/865816] [Cited by in Crossref: 160] [Cited by in F6Publishing: 163] [Article Influence: 22.9] [Reference Citation Analysis]
26 Zambirinis CP, Jarnagin WR. Letter to the editor regarding "Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers.". HPB (Oxford) 2020;22:1224. [PMID: 32563595 DOI: 10.1016/j.hpb.2020.05.007] [Reference Citation Analysis]
27 Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol 2011;13:39-51. [PMID: 22189424 DOI: 10.1038/nrm3255] [Cited by in Crossref: 355] [Cited by in F6Publishing: 324] [Article Influence: 32.3] [Reference Citation Analysis]
28 Kondratska K, Kondratskyi A, Yassine M, Lemonnier L, Lepage G, Morabito A, Skryma R, Prevarskaya N. Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma. Biochim Biophys Acta. 2014;1843:2263-2269. [PMID: 24583265 DOI: 10.1016/j.bbamcr.2014.02.012] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 8.1] [Reference Citation Analysis]
29 Bassagañas S, Carvalho S, Dias AM, Pérez-Garay M, Ortiz MR, Figueras J, Reis CA, Pinho SS, Peracaula R. Pancreatic cancer cell glycosylation regulates cell adhesion and invasion through the modulation of α2β1 integrin and E-cadherin function. PLoS One 2014;9:e98595. [PMID: 24878505 DOI: 10.1371/journal.pone.0098595] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
30 Callegari CC, Cavalli IJ, Lima RS, Jucoski TS, Torresan C, Urban CA, Kuroda F, Anselmi KF, Cavalli LR, Ribeiro EM. Copy number and expression analysis of FOSL1, GSTP1, NTSR1, FADD and CCND1 genes in primary breast tumors with axillary lymph node metastasis. Cancer Genetics 2016;209:331-9. [DOI: 10.1016/j.cancergen.2016.06.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
31 Ortiz-Zapater E, Pineda D, Martínez-Bosch N, Fernández-Miranda G, Iglesias M, Alameda F, Moreno M, Eliscovich C, Eyras E, Real FX. Key contribution of CPEB4-mediated translational control to cancer progression. Nat Med. 2012;18:83-90. [PMID: 22138752 DOI: 10.1038/nm.2540] [Cited by in Crossref: 92] [Cited by in F6Publishing: 93] [Article Influence: 8.4] [Reference Citation Analysis]
32 Tummers WS, Willmann JK, Bonsing BA, Vahrmeijer AL, Gambhir SS, Swijnenburg RJ. Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer. Pancreas 2018;47:675-89. [PMID: 29894417 DOI: 10.1097/MPA.0000000000001075] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
33 Song J, Xu Q, Zhang H, Yin X, Zhu C, Zhao K, Zhu J. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma. J Cell Biochem. 2018;119:4559-4569. [PMID: 29239017 DOI: 10.1002/jcb.26598] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
34 Ocaña A, Pandiella A. Personalized therapies in the cancer "omics" era. Mol Cancer 2010;9:202. [PMID: 20670437 DOI: 10.1186/1476-4598-9-202] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
35 Bartscht T, Rosien B, Rades D, Kaufmann R, Biersack H, Lehnert H, Gieseler F, Ungefroren H. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action. Mol Cancer 2015;14:199. [PMID: 26588899 DOI: 10.1186/s12943-015-0468-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
36 Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012;335:348-353. [PMID: 22157079 DOI: 10.1126/science.1212728] [Cited by in Crossref: 281] [Cited by in F6Publishing: 261] [Article Influence: 25.5] [Reference Citation Analysis]
37 Brini M, Carafoli E, Calì T. The plasma membrane calcium pumps: focus on the role in (neuro)pathology. Biochemical and Biophysical Research Communications 2017;483:1116-24. [DOI: 10.1016/j.bbrc.2016.07.117] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
38 Chiou SH, Dorsch M, Kusch E, Naranjo S, Kozak MM, Koong AC, Winslow MM, Grüner BM. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 2018;8:14008. [PMID: 30228296 DOI: 10.1038/s41598-018-32159-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
39 Jamieson NB, Chang DK, Grimmond SM, Biankin AV. Can we move towards personalised pancreatic cancer therapy? Expert Rev Gastroenterol Hepatol 2014;8:335-8. [PMID: 24702631 DOI: 10.1586/17474124.2014.893820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
40 Bailey KL, Carlson MA. Porcine Models of Pancreatic Cancer. Front Oncol 2019;9:144. [PMID: 30915276 DOI: 10.3389/fonc.2019.00144] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
41 Park D, Shakya R, Koivisto C, Pitarresi JR, Szabolcs M, Kladney R, Hadjis A, Mace TA, Ludwig T. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains. PLoS One 2019;14:e0226714. [PMID: 31877165 DOI: 10.1371/journal.pone.0226714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
42 Eng KH, Hanlon BM. Discrete mixture modeling to address genetic heterogeneity in time-to-event regression. Bioinformatics 2014;30:1690-7. [PMID: 24532723 DOI: 10.1093/bioinformatics/btu065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
43 Boca SM, Kinzler KW, Velculescu VE, Vogelstein B, Parmigiani G. Patient-oriented gene set analysis for cancer mutation data. Genome Biol 2010;11:R112. [PMID: 21092299 DOI: 10.1186/gb-2010-11-11-r112] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
44 Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther 2017;17:951-64. [PMID: 28817982 DOI: 10.1080/14737140.2017.1369882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
45 Wang Y, Su DW, Gao L, Ding GL, Ni CR, Zhu MH. Effect of NeuroD gene silencing on the migration and invasion of human pancreatic cancer cells PANC-1. Cell Biochem Biophys 2014;69:487-94. [PMID: 24464628 DOI: 10.1007/s12013-014-9822-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Rishi A, Goggins M, Wood LD, Hruban RH. Pathological and molecular evaluation of pancreatic neoplasms. Semin Oncol. 2015;42:28-39. [PMID: 25726050 DOI: 10.1053/j.seminoncol.2014.12.004] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
47 Sun L, Chua CY, Tian W, Zhang Z, Chiao PJ, Zhang W. MicroRNA Signaling Pathway Network in Pancreatic Ductal Adenocarcinoma. J Genet Genomics. 2015;42:563-577. [PMID: 26554910 DOI: 10.1016/j.jgg.2015.07.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
48 Alemar B, Izetti P, Gregório C, Macedo GS, Castro MA, Osvaldt AB, Matte U, Ashton-Prolla P. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma. Pancreas 2016;45:84-92. [PMID: 26262588 DOI: 10.1097/MPA.0000000000000383] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
49 Roukos DH. Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 2009;9:217-21. [PMID: 19379079 DOI: 10.1586/erm.09.7] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
50 Borrie AE, Maleki Vareki S. T Lymphocyte–Based Cancer Immunotherapeutics. Biology of T Cells - Part A. Elsevier; 2018. pp. 201-76. [DOI: 10.1016/bs.ircmb.2018.05.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
51 Springett GM, Husain K, Neuger A, Centeno B, Chen DT, Hutchinson TZ, Lush RM, Sebti S, Malafa MP. A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia. EBioMedicine 2015;2:1987-95. [PMID: 26844278 DOI: 10.1016/j.ebiom.2015.11.025] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
52 Wang H, Zheng X, Fei T, Wang J, Li X, Liu Y, Zhang F. Towards pathway-centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway. Clin Transl Med 2015;4:66. [PMID: 26220863 DOI: 10.1186/s40169-015-0066-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Shukla HD, Mahmood J, Vujaskovic Z. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer. Cancer Letters 2015;369:28-36. [DOI: 10.1016/j.canlet.2015.08.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
54 Corbo V, Ritelli R, Barbi S, Funel N, Campani D, Bardelli A, Scarpa A. Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. PLoS One 2010;5:e12653. [PMID: 20838624 DOI: 10.1371/journal.pone.0012653] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
55 Gress TM, Kestler HA, Lausser L, Fiedler L, Sipos B, Michalski CW, Werner J, Giese N, Scarpa A, Buchholz M. Differentiation of multiple types of pancreatico-biliary tumors by molecular analysis of clinical specimens. J Mol Med (Berl) 2012;90:457-64. [PMID: 22119958 DOI: 10.1007/s00109-011-0832-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
56 Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH, Patel SG, Wu N, Hindoyan A, Farrell JJ, Li X, Dawson DW, Wu H. Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 2012;18:1352-63. [PMID: 22261810 DOI: 10.1158/1078-0432.CCR-11-1539] [Cited by in Crossref: 131] [Cited by in F6Publishing: 93] [Article Influence: 13.1] [Reference Citation Analysis]
57 Song X, Chen H, Zhang C, Yu Y, Chen Z, Liang H, Van Buren G 2nd, McElhany AL, Fisher WE, Lonard DM, O'Malley BW, Wang J. SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma. Cancer Lett 2019;442:310-9. [PMID: 30423406 DOI: 10.1016/j.canlet.2018.11.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
58 Pan Z, Li L, Fang Q, Zhang Y, Hu X, Qian Y, Huang P. Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression. Cancer Cell Int 2018;18:214. [PMID: 30598639 DOI: 10.1186/s12935-018-0718-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
59 Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 2010;13:16-28. [PMID: 20061178 DOI: 10.1016/j.drup.2009.12.001] [Cited by in Crossref: 167] [Cited by in F6Publishing: 156] [Article Influence: 13.9] [Reference Citation Analysis]
60 Russell R, Perkhofer L, Liebau S, Lin Q, Lechel A, Feld FM, Hessmann E, Gaedcke J, Güthle M, Zenke M, Hartmann D, von Figura G, Weissinger SE, Rudolph KL, Möller P, Lennerz JK, Seufferlein T, Wagner M, Kleger A. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. Nat Commun 2015;6:7677. [PMID: 26220524 DOI: 10.1038/ncomms8677] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 8.4] [Reference Citation Analysis]
61 Maxwell JE, Sherman SK, Howe JR. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors. Clin Cancer Res 2016;22:5022-9. [PMID: 27742788 DOI: 10.1158/1078-0432.CCR-16-0435] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
62 Zhang J, Wu LY, Zhang XS, Zhang S. Discovery of co-occurring driver pathways in cancer. BMC Bioinformatics. 2014;15:271. [PMID: 25106096 DOI: 10.1186/1471-2105-15-271] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 7.4] [Reference Citation Analysis]
63 Kluckova K, Bezawork-Geleta A, Rohlena J, Dong L, Neuzil J. Mitochondrial complex II, a novel target for anti-cancer agents. Biochim Biophys Acta 2013;1827:552-64. [PMID: 23142170 DOI: 10.1016/j.bbabio.2012.10.015] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 7.3] [Reference Citation Analysis]
64 Schofield HK, Zeller J, Espinoza C, Halbrook CJ, Del Vecchio A, Magnuson B, Fabo T, Daylan AEC, Kovalenko I, Lee HJ, Yan W, Feng Y, Karim SA, Kremer DM, Kumar-Sinha C, Lyssiotis CA, Ljungman M, Morton JP, Galbán S, Fearon ER, Pasca di Magliano M. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. JCI Insight 2018;3:97422. [PMID: 29367463 DOI: 10.1172/jci.insight.97422] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
65 Legendre O, Sookdeo A, Foster DA. BxPC3 pancreatic cancer cells express a truncated Smad4 protein upon PI3K and mTOR inhibition. Oncol Lett 2014;7:1165-8. [PMID: 24944686 DOI: 10.3892/ol.2014.1833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
66 Zhou D, Yang L, Zheng L, Ge W, Li D, Zhang Y, Hu X, Gao Z, Xu J, Huang Y. Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesis. PLoS One. 2013;8:e53310. [PMID: 23301059 DOI: 10.1371/journal.pone.0053310] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
67 Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia 2012;14:690-701. [PMID: 22952422 DOI: 10.1593/neo.111810] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
68 Penet MF, Shah T, Bharti S, Krishnamachary B, Artemov D, Mironchik Y, Wildes F, Maitra A, Bhujwalla ZM. Metabolic imaging of pancreatic ductal adenocarcinoma detects altered choline metabolism. Clin Cancer Res 2015;21:386-95. [PMID: 25370468 DOI: 10.1158/1078-0432.CCR-14-0964] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
69 Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban CA, Scharpf R, White JR, O'Dwyer PJ, Allen PJ, Eshleman JR, Thompson CB, Klimstra DS, Linehan DC, Maitra A, Hruban RH, Diaz LA Jr, Von Hoff DD, Johansen JS, Drebin JA, Velculescu VE. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015;6:7686. [PMID: 26154128 DOI: 10.1038/ncomms8686] [Cited by in Crossref: 248] [Cited by in F6Publishing: 228] [Article Influence: 35.4] [Reference Citation Analysis]
70 Wu G, Feng X, Stein L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol 2010;11:R53. [PMID: 20482850 DOI: 10.1186/gb-2010-11-5-r53] [Cited by in Crossref: 424] [Cited by in F6Publishing: 378] [Article Influence: 35.3] [Reference Citation Analysis]
71 Xu R, Xu Q, Huang G, Yin X, Zhu J, Peng Y, Song J. Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma. Biomed Res Int 2019;2019:9379864. [PMID: 31956659 DOI: 10.1155/2019/9379864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
72 Borecka M, Zemankova P, Vocka M, Soucek P, Soukupova J, Kleiblova P, Sevcik J, Kleibl Z, Janatova M. Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic. Cancer Genetics 2016;209:199-204. [DOI: 10.1016/j.cancergen.2016.03.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
73 Cui Y, Niu M, Zhang X, Zhong Z, Wang J, Pang D. High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma. Tumour Biol 2015;36:9919-27. [PMID: 26168958 DOI: 10.1007/s13277-015-3748-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
74 Katoh M. Functional and cancer genomics of ASXL family members. Br J Cancer 2013;109:299-306. [PMID: 23736028 DOI: 10.1038/bjc.2013.281] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 8.7] [Reference Citation Analysis]
75 Paun BC, Kukuruga D, Jin Z, Mori Y, Cheng Y, Duncan M, Stass SA, Montgomery E, Hutcheon D, Meltzer SJ. Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas. Cancer. 2010;116:4495-4501. [PMID: 20572039 DOI: 10.1002/cncr.25348] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
76 Liot S, Balas J, Aubert A, Prigent L, Mercier-Gouy P, Verrier B, Bertolino P, Hennino A, Valcourt U, Lambert E. Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins. Front Immunol 2021;12:612271. [PMID: 33889150 DOI: 10.3389/fimmu.2021.612271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
77 Matthaios D, Zarogoulidis P, Balgouranidou I, Chatzaki E, Kakolyris S. Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology. 2011;81:259-272. [PMID: 22116519 DOI: 10.1159/000334449] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
78 Marchetti C, Zyner KG, Ohnmacht SA, Robson M, Haider SM, Morton JP, Marsico G, Vo T, Laughlin-Toth S, Ahmed AA, Di Vita G, Pazitna I, Gunaratnam M, Besser RJ, Andrade ACG, Diocou S, Pike JA, Tannahill D, Pedley RB, Evans TRJ, Wilson WD, Balasubramanian S, Neidle S. Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule. J Med Chem 2018;61:2500-17. [PMID: 29356532 DOI: 10.1021/acs.jmedchem.7b01781] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 15.5] [Reference Citation Analysis]
79 Rabien A, Sanchez-ruderisch H, Schulz P, Otto N, Wimmel A, Wiedenmann B, Detjen KM. Tumor suppressor p16INK4a controls oncogenic K-Ras function in human pancreatic cancer cells. Cancer Science 2012;103:169-75. [DOI: 10.1111/j.1349-7006.2011.02140.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
80 Ng PC, Kirkness EF. Whole genome sequencing. Methods Mol Biol 2010;628:215-26. [PMID: 20238084 DOI: 10.1007/978-1-60327-367-1_12] [Cited by in Crossref: 105] [Cited by in F6Publishing: 62] [Article Influence: 8.8] [Reference Citation Analysis]
81 Poruk KE, Firpo MA, Mulvihill SJ. Screening for pancreatic cancer. Adv Surg 2014;48:115-36. [PMID: 25293611 DOI: 10.1016/j.yasu.2014.05.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
82 Kong X, Li L, Li Z, Xie K. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Cytokine Growth Factor Rev 2012;23:343-56. [PMID: 22749856 DOI: 10.1016/j.cytogfr.2012.06.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
83 Awasthi N, Monahan S, Stefaniak A, Schwarz MA, Schwarz RE. Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Oncotarget 2018;9:5274-86. [PMID: 29435178 DOI: 10.18632/oncotarget.23684] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
84 Sinkala M, Mulder N, Martin DP. Integrative landscape of dysregulated signaling pathways of clinically distinct pancreatic cancer subtypes. Oncotarget 2018;9:29123-39. [PMID: 30018740 DOI: 10.18632/oncotarget.25632] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
85 Eshleman JR, Norris AL, Sadakari Y, Debeljak M, Borges M, Harrington C, Lin E, Brant A, Barkley T, Almario JA, Topazian M, Farrell J, Syngal S, Lee JH, Yu J, Hruban RH, Kanda M, Canto MI, Goggins M. KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. Clin Gastroenterol Hepatol 2015;13:963-9.e4. [PMID: 25481712 DOI: 10.1016/j.cgh.2014.11.028] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
86 Hamann J, Aust G, Araç D, Engel FB, Formstone C, Fredriksson R, Hall RA, Harty BL, Kirchhoff C, Knapp B, Krishnan A, Liebscher I, Lin HH, Martinelli DC, Monk KR, Peeters MC, Piao X, Prömel S, Schöneberg T, Schwartz TW, Singer K, Stacey M, Ushkaryov YA, Vallon M, Wolfrum U, Wright MW, Xu L, Langenhan T, Schiöth HB. International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors. Pharmacol Rev 2015;67:338-67. [PMID: 25713288 DOI: 10.1124/pr.114.009647] [Cited by in Crossref: 222] [Cited by in F6Publishing: 203] [Article Influence: 31.7] [Reference Citation Analysis]
87 Takagi K, Imura J, Shimomura A, Noguchi A, Minamisaka T, Tanaka S, Nishida T, Hatta H, Nakajima T. Establishment of highly invasive pancreatic cancer cell lines and the expression of IL-32. Oncol Lett 2020;20:2888-96. [PMID: 32782605 DOI: 10.3892/ol.2020.11825] [Reference Citation Analysis]
88 Lee S, Park J, Jeong S, Kim B, Kang Y, Xu Y, Chung S. K120R mutation inactivates p53 by creating an aberrant splice site leading to nonsense-mediated mRNA decay. Oncogene 2019;38:1597-610. [DOI: 10.1038/s41388-018-0542-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
89 Mohammed A, Janakiram NB, Pant S, Rao CV. Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel) 2015;7:1499-542. [PMID: 26266422 DOI: 10.3390/cancers7030850] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
90 Zhan Q, Fang Y, Deng X, Chen H, Jin J, Lu X, Peng C, Li H, Shen B. The Interplay Between miR-148a and DNMT1 Might be Exploited for Pancreatic Cancer Therapy. Cancer Invest 2015;33:267-75. [PMID: 25950085 DOI: 10.3109/07357907.2015.1025794] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
91 Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 2009;208:781-7; discussion 787-9. [PMID: 19476837 DOI: 10.1016/j.jamcollsurg.2008.12.018] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 6.7] [Reference Citation Analysis]
92 Lodestijn SC, van Neerven SM, Vermeulen L, Bijlsma MF. Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer. Cancers (Basel) 2021;13:3295. [PMID: 34209288 DOI: 10.3390/cancers13133295] [Reference Citation Analysis]
93 Ding L, Wendl MC, Koboldt DC, Mardis ER. Analysis of next-generation genomic data in cancer: accomplishments and challenges. Hum Mol Genet 2010;19:R188-96. [PMID: 20843826 DOI: 10.1093/hmg/ddq391] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 7.7] [Reference Citation Analysis]
94 Brunner M, Wu Z, Krautz C, Pilarsky C, Grützmann R, Weber GF. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Int J Mol Sci 2019;20:E4543. [PMID: 31540286 DOI: 10.3390/ijms20184543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
95 Poage GM, Christensen BC, Houseman EA, McClean MD, Wiencke JK, Posner MR, Clark JR, Nelson HH, Marsit CJ, Kelsey KT. Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted. PLoS One 2010;5:e9651. [PMID: 20300172 DOI: 10.1371/journal.pone.0009651] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
96 Mohelnikova-Duchonova B, Kocik M, Duchonova B, Brynychova V, Oliverius M, Hlavsa J, Honsova E, Mazanec J, Kala Z, Ojima I, Hughes DJ, Doherty JE, Murray HA, Crockard MA, Lemstrova R, Soucek P. Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. Pharmacogenomics J 2017;17:452-60. [PMID: 27573236 DOI: 10.1038/tpj.2016.55] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
97 Hao J, Zhang S, Zhou Y, Liu C, Hu X, Shao C. MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer. Biochem Biophys Res Commun. 2011;406:552-557. [PMID: 21352803 DOI: 10.1016/j.bbrc.2011.02.086] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 6.6] [Reference Citation Analysis]
98 Au W, Ruchirawat M. Biomarkers in Population Studies: Environmental Mutagenesis and Risk for Cancer. Reviews on Environmental Health 2009;24. [DOI: 10.1515/reveh.2009.24.2.117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
99 Dupuy AJ, Rogers LM, Kim J, Nannapaneni K, Starr TK, Liu P, Largaespada DA, Scheetz TE, Jenkins NA, Copeland NG. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res 2009;69:8150-6. [PMID: 19808965 DOI: 10.1158/0008-5472.CAN-09-1135] [Cited by in Crossref: 127] [Cited by in F6Publishing: 94] [Article Influence: 9.8] [Reference Citation Analysis]
100 Sinha A, Cherba D, Bartlam H, Lenkiewicz E, Evers L, Barrett MT, Haab BB. Mesenchymal-like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial-like counterparts. Mol Oncol 2014;8:1253-65. [PMID: 24837184 DOI: 10.1016/j.molonc.2014.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
101 Nadolny C, Dong X. Liver receptor homolog-1 (LRH-1): a potential therapeutic target for cancer. Cancer Biol Ther 2015;16:997-1004. [PMID: 25951367 DOI: 10.1080/15384047.2015.1045693] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
102 Felsenstein M, Hruban RH, Wood LD. New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Adv Anat Pathol. 2018;25:131-142. [PMID: 28914620 DOI: 10.1097/pap.0000000000000172] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
103 Momtaz P, O'Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, Berger MF, Kelsen DP, Suehnholz SP, Chakravarty D, Yu KH, Varghese AM, Zervoudakis A, Li J, Ku GY, Park JS, Shcherba M, Harding JJ, Goldberg Z, Abou-Alfa GK, Salo-Mullen EE, Stadler ZK, Iacobuzio-Donahue CA, O'Reilly EM. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Cancer 2021. [PMID: 34351646 DOI: 10.1002/cncr.33812] [Reference Citation Analysis]
104 Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136:823-837. [PMID: 19269363 DOI: 10.1016/j.cell.2009.02.024] [Cited by in Crossref: 1182] [Cited by in F6Publishing: 1082] [Article Influence: 90.9] [Reference Citation Analysis]
105 Gozdecka M, Breitwieser W. The roles of ATF2 (activating transcription factor 2) in tumorigenesis. Biochem Soc Trans 2012;40:230-4. [PMID: 22260696 DOI: 10.1042/BST20110630] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
106 Nikolaienko RM, Agyekum B, Bouyain S. Receptor protein tyrosine phosphatases and cancer: new insights from structural biology. Cell Adh Migr 2012;6:356-64. [PMID: 22796942 DOI: 10.4161/cam.21242] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
107 Peacock ZS, Kademani D, Le AD, Lee JS, Hale RG, Cunningham LL. Proceedings From the 2011 American Association of Oral and Maxillofacial Surgeons Research Summit. Journal of Oral and Maxillofacial Surgery 2012;70:1271-9. [DOI: 10.1016/j.joms.2012.01.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
108 Zhang Y, Yan W, Mathew E, Bednar F, Wan S, Collins MA, Evans RA, Welling TH, Vonderheide RH, di Magliano MP. CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer Immunol Res 2014;2:423-35. [PMID: 24795355 DOI: 10.1158/2326-6066.CIR-14-0016-T] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
109 Winnard PT Jr, Bharti SK, Penet MF, Marik R, Mironchik Y, Wildes F, Maitra A, Bhujwalla ZM. Detection of Pancreatic Cancer-Induced Cachexia Using a Fluorescent Myoblast Reporter System and Analysis of Metabolite Abundance. Cancer Res 2016;76:1441-50. [PMID: 26719527 DOI: 10.1158/0008-5472.CAN-15-1740] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
110 Jiang J, Azevedo-Pouly AC, Redis RS, Lee EJ, Gusev Y, Allard D, Sutaria DS, Badawi M, Elgamal OA, Lerner MR, Brackett DJ, Calin GA, Schmittgen TD. Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma. Oncotarget 2016;7:53165-77. [PMID: 27363020 DOI: 10.18632/oncotarget.10242] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
111 Aguilera KY, Dawson DW. WNT Ligand Dependencies in Pancreatic Cancer. Front Cell Dev Biol 2021;9:671022. [PMID: 33996827 DOI: 10.3389/fcell.2021.671022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
112 Basso D, Bozzato D, Padoan A, Moz S, Zambon CF, Fogar P, Greco E, Scorzeto M, Simonato F, Navaglia F, Fassan M, Pelloso M, Dupont S, Pedrazzoli S, Fassina A, Plebani M. Inflammation and pancreatic cancer: molecular and functional interactions between S100A8, S100A9, NT-S100A8 and TGFβ1. Cell Commun Signal 2014;12:20. [PMID: 24670043 DOI: 10.1186/1478-811X-12-20] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
113 Zhang J, Baran J, Cros A, Guberman JM, Haider S, Hsu J, Liang Y, Rivkin E, Wang J, Whitty B, Wong-Erasmus M, Yao L, Kasprzyk A. International Cancer Genome Consortium Data Portal--a one-stop shop for cancer genomics data. Database (Oxford) 2011;2011:bar026. [PMID: 21930502 DOI: 10.1093/database/bar026] [Cited by in Crossref: 283] [Cited by in F6Publishing: 280] [Article Influence: 25.7] [Reference Citation Analysis]
114 Malaney P, Nicosia SV, Davé V. One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett 2014;344:1-12. [PMID: 24157811 DOI: 10.1016/j.canlet.2013.10.010] [Cited by in Crossref: 184] [Cited by in F6Publishing: 160] [Article Influence: 20.4] [Reference Citation Analysis]
115 Kurahara H, Maemura K, Mataki Y, Sakoda M, Shinchi H, Natsugoe S. Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer. World J Surg 2016;40:1977-84. [DOI: 10.1007/s00268-016-3477-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
116 Yamaguchi J, Yokoyama Y, Kokuryo T, Ebata T, Nagino M. Cells of origin of pancreatic neoplasms. Surg Today. 2018;48:9-17. [PMID: 28260136 DOI: 10.1007/s00595-017-1501-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
117 Afify A, Huang EC, Jeong M, Urayama S. Immunoisolation of pancreatic epithelial cells from endoscopic ultrasound-guided fine needle aspirates with magnetic beads for downstream molecular application: ISOLATING PANCREATIC DUCTAL CELLS FROM FNA. Diagn Cytopathol 2016;44:32-8. [DOI: 10.1002/dc.23383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Becker SF, Langhe R, Huang C, Wedlich D, Kashef J. Giving the right tug for migration: Cadherins in tissue movements. Archives of Biochemistry and Biophysics 2012;524:30-42. [DOI: 10.1016/j.abb.2012.02.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
119 Maresch R, Mueller S, Veltkamp C, Öllinger R, Friedrich M, Heid I, Steiger K, Weber J, Engleitner T, Barenboim M, Klein S, Louzada S, Banerjee R, Strong A, Stauber T, Gross N, Geumann U, Lange S, Ringelhan M, Varela I, Unger K, Yang F, Schmid RM, Vassiliou GS, Braren R, Schneider G, Heikenwalder M, Bradley A, Saur D, Rad R. Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice. Nat Commun 2016;7:10770. [PMID: 26916719 DOI: 10.1038/ncomms10770] [Cited by in Crossref: 102] [Cited by in F6Publishing: 92] [Article Influence: 17.0] [Reference Citation Analysis]
120 Roukos DH. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 2010;28:e279-80; author reply e282-3. [PMID: 20406920 DOI: 10.1200/JCO.2009.27.7061] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
121 Zacher B, Abnaof K, Gade S, Younesi E, Tresch A, Fröhlich H. Joint Bayesian inference of condition-specific miRNA and transcription factor activities from combined gene and microRNA expression data. Bioinformatics 2012;28:1714-20. [PMID: 22563068 DOI: 10.1093/bioinformatics/bts257] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
122 Lin MT, Tseng LH, Kamiyama H, Kamiyama M, Lim P, Hidalgo M, Wheelan S, Eshleman J. Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. Biotechniques 2010;48:211-8. [PMID: 20359302 DOI: 10.2144/000113363] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
123 Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ, Nickerson DA, Corey E, Lange PH, Morrissey C, Vessella RL, Nelson PS, Shendure J. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A 2011;108:17087-92. [PMID: 21949389 DOI: 10.1073/pnas.1108745108] [Cited by in Crossref: 187] [Cited by in F6Publishing: 177] [Article Influence: 17.0] [Reference Citation Analysis]
124 Biasutto L, Dong LF, Zoratti M, Neuzil J. Mitochondrially targeted anti-cancer agents. Mitochondrion. 2010;10:670-681. [PMID: 20601192 DOI: 10.1016/j.mito.2010.06.004] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 7.3] [Reference Citation Analysis]
125 Wang BD, Yang Q, Ceniccola K, Bianco F, Andrawis R, Jarrett T, Frazier H, Patierno SR, Lee NH. Androgen receptor-target genes in african american prostate cancer disparities. Prostate Cancer 2013;2013:763569. [PMID: 23365759 DOI: 10.1155/2013/763569] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
126 Munding J, Lüttges J, Esposito I, Tannapfel A. [Update of the S3 guidelines for pancreatic cancer. What is new for pathologists?]. Pathologe 2014;35:509-18; quiz 518-20. [PMID: 24981895 DOI: 10.1007/s00292-012-1712-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
127 Liu L, Zhi Q, Shen M, Gong FR, Zhou BP, Lian L, Shen B, Chen K, Duan W, Wu MY, Tao M, Li W. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Oncotarget 2016;7:47145-62. [PMID: 27323403 DOI: 10.18632/oncotarget.9975] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
128 Saiki Y, Horii A. Molecular pathology of pancreatic cancer. Pathol Int 2014;64:10-9. [PMID: 24471965 DOI: 10.1111/pin.12114] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
129 Cox AD, Olive KP. Silencing the killers: paracrine immune suppression in pancreatic cancer. Cancer Cell 2012;21:715-6. [PMID: 22698396 DOI: 10.1016/j.ccr.2012.05.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
130 Landrette SF, Xu T. Somatic genetics empowers the mouse for modeling and interrogating developmental and disease processes. PLoS Genet 2011;7:e1002110. [PMID: 21814514 DOI: 10.1371/journal.pgen.1002110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
131 Mortoglou M, Tabin ZK, Arisan ED, Kocher HM, Uysal-Onganer P. Non-coding RNAs in pancreatic ductal adenocarcinoma: New approaches for better diagnosis and therapy. Transl Oncol 2021;14:101090. [PMID: 33831655 DOI: 10.1016/j.tranon.2021.101090] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Maron R, Schechter B, Nataraj NB, Ghosh S, Romaniello D, Marrocco I, Noronha A, Carvalho S, Yarden Y, Sela M. Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies. Biochem Biophys Res Commun 2019;513:219-25. [PMID: 30952434 DOI: 10.1016/j.bbrc.2019.03.204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12:621-628. [PMID: 22845482 DOI: 10.1586/erm.12.46] [Cited by in Crossref: 111] [Cited by in F6Publishing: 108] [Article Influence: 11.1] [Reference Citation Analysis]
134 Washington MK, Goldberg RM, Chang GJ, Limburg P, Lam AK, Salto-Tellez M, Arends MJ, Nagtegaal ID, Klimstra DS, Rugge M, Schirmacher P, Lazar AJ, Odze RD, Carneiro F, Fukayama M, Cree IA; WHO Classification of Tumours Editorial Board. Diagnosis of digestive system tumours. Int J Cancer 2021;148:1040-50. [PMID: 32674220 DOI: 10.1002/ijc.33210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
135 Ledford H. Big science: The cancer genome challenge. Nature 2010;464:972-4. [PMID: 20393534 DOI: 10.1038/464972a] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
136 Liu S. Increasing alternative promoter repertories is positively associated with differential expression and disease susceptibility. PLoS One 2010;5:e9482. [PMID: 20208995 DOI: 10.1371/journal.pone.0009482] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
137 Alessandrino F, Smith DA, Tirumani SH, Ramaiya NH. Cancer genome landscape: a radiologist's guide to cancer genome medicine with imaging correlates. Insights Imaging 2019;10:111. [PMID: 31781977 DOI: 10.1186/s13244-019-0800-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Ciernikova S, Earl J, García Bermejo ML, Stevurkova V, Carrato A, Smolkova B. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance? Int J Mol Sci 2020;21:E4091. [PMID: 32521716 DOI: 10.3390/ijms21114091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
139 Lindberg J, Lundeberg J. The plasticity of the mammalian transcriptome. Genomics 2010;95:1-6. [PMID: 19716875 DOI: 10.1016/j.ygeno.2009.08.010] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
140 Nilsson LN, Keane MG, Shamali A, Millastre Bocos J, Marijinissen van Zanten M, Antila A, Verdejo Gil C, Del Chiaro M, Laukkarinen J. Nature and management of pancreatic mucinous cystic neoplasm (MCN): A systematic review of the literature. Pancreatology. 2016;16:1028-1036. [PMID: 27681503 DOI: 10.1016/j.pan.2016.09.011] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
141 Chan MP, Plouffe KR, Liu CJ, Palanisamy N, Carskadon S, Zhao L, Nazarian RM, Durham AB, Johnson TM, Andea AA, Patel RM, Lowe L, Fullen DR, Brown NA, Tomlins SA, Udager AM, Harms PW. Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas. Mod Pathol 2020;33:1092-103. [PMID: 31857679 DOI: 10.1038/s41379-019-0424-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
142 Wang K, Baldwin GS, Nikfarjam M, He H. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World J Gastroenterol 2018; 24(33): 3709-3723 [PMID: 30197477 DOI: 10.3748/wjg.v24.i33.3709] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
143 Ware MB, El-Rayes BF, Lesinski GB. Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer. J Immunother Cancer 2020;8:e001100. [PMID: 32843336 DOI: 10.1136/jitc-2020-001100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Lee JY, Kim HS, Suh DH, Kim MK, Chung HH, Song YS. Ovarian cancer biomarker discovery based on genomic approaches. J Cancer Prev 2013;18:298-312. [PMID: 25337559 DOI: 10.15430/jcp.2013.18.4.298] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
146 Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, Buonaguro L. Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother 2014;10:3332-46. [PMID: 25483639 DOI: 10.4161/21645515.2014.973317] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 10.4] [Reference Citation Analysis]
147 Muzumdar MD, Chen PY, Dorans KJ, Chung KM, Bhutkar A, Hong E, Noll EM, Sprick MR, Trumpp A, Jacks T. Survival of pancreatic cancer cells lacking KRAS function. Nat Commun 2017;8:1090. [PMID: 29061961 DOI: 10.1038/s41467-017-00942-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 14.0] [Reference Citation Analysis]
148 Firpo MA, Boucher KM, Mulvihill SJ. Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers. Theor Biol Med Model 2014;11:34. [PMID: 25096727 DOI: 10.1186/1742-4682-11-34] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
149 Samore WR, Gondi CS. Brief overview of selected approaches in targeting pancreatic adenocarcinoma. Expert Opin Investig Drugs 2014;23:793-807. [PMID: 24673265 DOI: 10.1517/13543784.2014.902933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
150 Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett. 2013;335:41-51. [PMID: 23402814 DOI: 10.1016/j.canlet.2013.01.054] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 10.4] [Reference Citation Analysis]
151 Narayanan V, Weekes CD. Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol 2016; 8(4): 366-379 [PMID: 27096032 DOI: 10.4251/wjgo.v8.i4.366] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
152 Goess R, Friess H. A look at the progress of treating pancreatic cancer over the past 20 years. Expert Rev Anticancer Ther. 2018;18:295-304. [PMID: 29334794 DOI: 10.1080/14737140.2018.1428093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
153 Da Ros VG, Gutierrez-Perez I, Ferres-Marco D, Dominguez M. Dampening the signals transduced through hedgehog via microRNA miR-7 facilitates notch-induced tumourigenesis. PLoS Biol 2013;11:e1001554. [PMID: 23667323 DOI: 10.1371/journal.pbio.1001554] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
154 Kleger A, Perkhofer L, Seufferlein T. Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol. 2014;25:1260-1270. [PMID: 24631947 DOI: 10.1093/annonc/mdu013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
155 Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 2011;17:5793-800. [PMID: 21742805 DOI: 10.1158/1078-0432.CCR-11-0341] [Cited by in Crossref: 148] [Cited by in F6Publishing: 97] [Article Influence: 13.5] [Reference Citation Analysis]
156 Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res. 2015;3:399-411. [PMID: 25678581 DOI: 10.1158/2326-6066.cir-14-0215] [Cited by in Crossref: 242] [Cited by in F6Publishing: 171] [Article Influence: 34.6] [Reference Citation Analysis]
157 Mollaei M, Hassan ZM, Khorshidi F, Langroudi L. Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells? Transl Oncol 2021;14:101056. [PMID: 33684837 DOI: 10.1016/j.tranon.2021.101056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Onvani S, Etame AB, Smith CA, Rutka JT. Genetics of medulloblastoma: clues for novel therapies. Expert Rev Neurother 2010;10:811-23. [PMID: 20420498 DOI: 10.1586/ern.10.31] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
159 Subramani R, Lopez-Valdez R, Salcido A, Boopalan T, Arumugam A, Nandy S, Lakshmanaswamy R. Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma. Exp Mol Med 2014;46:e117. [PMID: 25301264 DOI: 10.1038/emm.2014.61] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
160 Dayton JB, Piccolo SR. Classifying cancer genome aberrations by their mutually exclusive effects on transcription. BMC Med Genomics 2017;10:66. [PMID: 29322935 DOI: 10.1186/s12920-017-0303-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
161 Su Y, Li J, Shi C, Hruban RH, Radice GL. N-cadherin functions as a growth suppressor in a model of K-ras-induced PanIN. Oncogene 2016;35:3335-41. [PMID: 26477318 DOI: 10.1038/onc.2015.382] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
162 Polvani S, Tarocchi M, Tempesti S, Galli A. Nuclear receptors and pathogenesis of pancreatic cancer. World J Gastroenterol 2014; 20(34): 12062-12081 [PMID: 25232244 DOI: 10.3748/wjg.v20.i34.12062] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
163 Gentry LR, Martin TD, Reiner DJ, Der CJ. Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame. Biochim Biophys Acta 2014;1843:2976-88. [PMID: 25219551 DOI: 10.1016/j.bbamcr.2014.09.004] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 8.8] [Reference Citation Analysis]
164 Li D, Yang M, Liang M, Mei C, Lin Y, Yang F, Xiao Y, Chen Y, Wang F, Mao J, Su Z. c-Met-targeted near-infrared fluorescent probe for real-time depiction and dissection of perineural invasion and lymph node metastasis lesions in pancreatic ductal adenocarcinoma xenograft models. Biomater Sci 2021. [PMID: 34254599 DOI: 10.1039/d1bm00674f] [Reference Citation Analysis]
165 Bastians H. Causes of Chromosomal Instability. Recent Results Cancer Res. 2015;200:95-113. [PMID: 26376874 DOI: 10.1007/978-3-319-20291-4_5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
166 Simon R. Translational research in oncology: key bottlenecks and new paradigms. Expert Rev Mol Med 2010;12. [DOI: 10.1017/s1462399410001638] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
167 Kong B, Bruns P, Behler NA, Chang L, Schlitter AM, Cao J, Gewies A, Ruland J, Fritzsche S, Valkovskaya N, Jian Z, Regel I, Raulefs S, Irmler M, Beckers J, Friess H, Erkan M, Mueller NS, Roth S, Hackert T, Esposito I, Theis FJ, Kleeff J, Michalski CW. Dynamic landscape of pancreatic carcinogenesis reveals early molecular networks of malignancy. Gut 2018;67:146-56. [PMID: 27646934 DOI: 10.1136/gutjnl-2015-310913] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
168 Tuntithavornwat S, Shea DJ, Wong BS, Guardia T, Lee SJ, Yankaskas CL, Zheng L, Kontrogianni-Konstantopoulos A, Konstantopoulos K. Giant obscurin regulates migration and metastasis via RhoA-dependent cytoskeletal remodeling in pancreatic cancer. Cancer Lett 2022;526:155-67. [PMID: 34826548 DOI: 10.1016/j.canlet.2021.11.016] [Reference Citation Analysis]
169 Garcia-Carracedo D, Chen ZM, Qiu W, Huang AS, Tang SM, Hruban RH, Su GH. PIK3CA mutations in mucinous cystic neoplasms of the pancreas. Pancreas. 2014;43:245-249. [PMID: 24518503 DOI: 10.1097/mpa.0000000000000034] [Cited by in Crossref: 40] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
170 Whibley C, Odell AF, Nedelko T, Balaburski G, Murphy M, Liu Z, Stevens L, Walker JH, Routledge M, Hollstein M. Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. J Biol Chem 2010;285:11326-35. [PMID: 20118236 DOI: 10.1074/jbc.M109.064444] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
171 Vassaux G, Angelova A, Baril P, Midoux P, Rommelaere J, Cordelier P. The Promise of Gene Therapy for Pancreatic Cancer. Hum Gene Ther 2016;27:127-33. [PMID: 26603492 DOI: 10.1089/hum.2015.141] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
172 Schweiger MR, Kerick M, Timmermann B, Isau M. The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations. Cancer Metastasis Rev 2011;30:199-210. [PMID: 21267768 DOI: 10.1007/s10555-011-9278-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
173 Malinova A, Veghini L, Real FX, Corbo V. Cell Lineage Infidelity in PDAC Progression and Therapy Resistance. Front Cell Dev Biol 2021;9:795251. [PMID: 34926472 DOI: 10.3389/fcell.2021.795251] [Reference Citation Analysis]
174 Li DF, Lian L, Qu LJ, Chen YM, Liu WB, Chen SR, Zheng JX, Xu GY, Yang N. A genome-wide SNP scan reveals two loci associated with the chicken resistance to Marek's disease. Anim Genet 2013;44:217-22. [PMID: 22812605 DOI: 10.1111/j.1365-2052.2012.02395.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
175 Kann MG. Advances in translational bioinformatics: computational approaches for the hunting of disease genes. Brief Bioinform 2010;11:96-110. [PMID: 20007728 DOI: 10.1093/bib/bbp048] [Cited by in Crossref: 61] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
176 Gong Y, Zhang L, Zhang A, Chen X, Gao P, Zeng Q. GATA4 inhibits cell differentiation and proliferation in pancreatic cancer. PLoS One 2018;13:e0202449. [PMID: 30142155 DOI: 10.1371/journal.pone.0202449] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
177 Oyasiji T, Ma WW. Novel adjuvant therapies for pancreatic adenocarcinoma. J Gastrointest Oncol 2015;6:430-5. [PMID: 26261729 DOI: 10.3978/j.issn.2078-6891.2015.031] [Reference Citation Analysis]
178 Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15-22. [PMID: 22729569 DOI: 10.1002/jso.23192] [Cited by in Crossref: 137] [Cited by in F6Publishing: 141] [Article Influence: 13.7] [Reference Citation Analysis]
179 von Figura G, Fukuda A, Roy N, Liku ME, Morris Iv JP, Kim GE, Russ HA, Firpo MA, Mulvihill SJ, Dawson DW, Ferrer J, Mueller WF, Busch A, Hertel KJ, Hebrok M. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat Cell Biol 2014;16:255-67. [PMID: 24561622 DOI: 10.1038/ncb2916] [Cited by in Crossref: 122] [Cited by in F6Publishing: 102] [Article Influence: 15.3] [Reference Citation Analysis]
180 Balakrishnan A, Penachioni JY, Lamba S, Bleeker FE, Zanon C, Rodolfo M, Vallacchi V, Scarpa A, Felicioni L, Buck M, Marchetti A, Comoglio PM, Bardelli A, Tamagnone L. Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. Hum Mutat 2009;30:1167-74. [PMID: 19462467 DOI: 10.1002/humu.21017] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
181 Liu Z, Li D, Yu L, Niu F. Gallic acid as a cancer-selective agent induces apoptosis in pancreatic cancer cells. Chemotherapy. 2012;58:185-194. [PMID: 22739044 DOI: 10.1159/000337103] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
182 Brune KA, Lau B, Palmisano E, Canto M, Goggins MG, Hruban RH, Klein AP. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010;102:119-126. [PMID: 20068195 DOI: 10.1093/jnci/djp466] [Cited by in Crossref: 117] [Cited by in F6Publishing: 112] [Article Influence: 9.8] [Reference Citation Analysis]
183 Asting AG, Ljungman D, Carén H, Dambrauskas Z, Iresjö BM, Hyltander A, Naredi P, Lundholm K. Alterations in Tumor DNA Are Related to Short Postoperative Survival in Patients Resected for Pancreatic Carcinoma Aimed at Cure. Pancreas 2016;45:900-7. [PMID: 26684859 DOI: 10.1097/MPA.0000000000000566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
184 van Mackelenbergh MG, Stroes CI, Spijker R, van Eijck CHJ, Wilmink JW, Bijlsma MF, van Laarhoven HWM. Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 31035512 DOI: 10.3390/cancers11050588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
185 Liang S, Zhang R, Liang D, Song T, Ai T, Xia C, Xia L, Wang Y. Multimodal 3D DenseNet for IDH Genotype Prediction in Gliomas. Genes (Basel) 2018;9:E382. [PMID: 30061525 DOI: 10.3390/genes9080382] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 12.5] [Reference Citation Analysis]
186 Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 2013;45:1474-8. [PMID: 24185513 DOI: 10.1038/ng.2806] [Cited by in Crossref: 282] [Cited by in F6Publishing: 322] [Article Influence: 31.3] [Reference Citation Analysis]
187 Chen PY, Muzumdar MD, Dorans KJ, Robbins R, Bhutkar A, Del Rosario A, Mertins P, Qiao J, Schafer AC, Gertler F, Carr S, Jacks T. Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Res 2018;78:985-1002. [PMID: 29279356 DOI: 10.1158/0008-5472.CAN-17-2129] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
188 Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. Immunotherapy. 2016;8:117-125. [PMID: 26787078 DOI: 10.2217/imt.15.113] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
189 Güngör C, Hofmann BT, Wolters-Eisfeld G, Bockhorn M. Pancreatic cancer. Br J Pharmacol. 2014;171:849-858. [PMID: 24024905 DOI: 10.1111/bph.12401] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
190 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.3322/caac.21190] [Cited by in Crossref: 479] [Cited by in F6Publishing: 473] [Article Influence: 53.2] [Reference Citation Analysis]
191 Wu X, Li G. Prevalent Accumulation of Non-Optimal Codons through Somatic Mutations in Human Cancers. PLoS One 2016;11:e0160463. [PMID: 27513638 DOI: 10.1371/journal.pone.0160463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
192 Barreto SG. Does biology determine survival in pancreatic cancer? Future Oncol 2020;16:1-4. [PMID: 31872770 DOI: 10.2217/fon-2019-0706] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
193 Zhang J, Wang L. The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review. Technol Cancer Res Treat 2019;18:1533033819831068. [PMID: 30798772 DOI: 10.1177/1533033819831068] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 17.3] [Reference Citation Analysis]
194 Graham JS, Jamieson NB, Rulach R, Grimmond SM, Chang DK, Biankin AV. Pancreatic cancer genomics: where can the science take us? Clin Genet 2015;88:213-9. [PMID: 25388820 DOI: 10.1111/cge.12536] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
195 Hlavac V, Mohelnikova-Duchonova B, Lovecek M, Ehrmann J, Brynychova V, Kolarova K, Soucek P. Targeted Sequencing of Pancreatic Adenocarcinomas from Patients with Metachronous Pulmonary Metastases. Genes (Basel) 2020;11:E1391. [PMID: 33255265 DOI: 10.3390/genes11121391] [Reference Citation Analysis]
196 Ganaie AA, Siddique HR, Sheikh IA, Parray A, Wang L, Panyam J, Villalta PW, Deng Y, Konety BR, Saleem M. A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems. Mol Carcinog 2020;59:886-96. [PMID: 32291806 DOI: 10.1002/mc.23200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018;8:1096-1111. [PMID: 29903880 DOI: 10.1158/2159-8290.cd-18-0275] [Cited by in Crossref: 113] [Cited by in F6Publishing: 72] [Article Influence: 28.3] [Reference Citation Analysis]
198 Kolsi LE, Leal AS, Yli-Kauhaluoma J, Liby KT, Moreira VM. Dehydroabietic oximes halt pancreatic cancer cell growth in the G1 phase through induction of p27 and downregulation of cyclin D1. Sci Rep 2018;8:15923. [PMID: 30374056 DOI: 10.1038/s41598-018-34131-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
199 Wang D, Liu K, Yang Y, Wang T, Rao Q, Guo W, Zhang Z. Prognostic value of leukemia inhibitory factor and its receptor in pancreatic adenocarcinoma. Future Oncol 2020;16:4461-73. [PMID: 31854204 DOI: 10.2217/fon-2019-0684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
200 Nagathihalli NS, Nagaraju G. RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Biochim Biophys Acta 2011;1816:209-18. [PMID: 21807066 DOI: 10.1016/j.bbcan.2011.07.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 30] [Article Influence: 1.2] [Reference Citation Analysis]
201 Fiorino S, Lorenzini S, Masetti M, Deleonardi G, Grondona AG, Silvestri T, Chili E, Del Prete P, Bacchi-Reggiani L, Cuppini A. Hepatitis B and C virus infections as possible risk factor for pancreatic adenocarcinoma. Med Hypotheses. 2012;79:678-697. [PMID: 22959312 DOI: 10.1016/j.mehy.2012.08.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
202 Notta F, Hahn SA, Real FX. A genetic roadmap of pancreatic cancer: still evolving. Gut. 2017;66:2170-2178. [PMID: 28993418 DOI: 10.1136/gutjnl-2016-313317] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
203 Hüttenhain R, Soste M, Selevsek N, Röst H, Sethi A, Carapito C, Farrah T, Deutsch EW, Kusebauch U, Moritz RL, Niméus-Malmström E, Rinner O, Aebersold R. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med. 2012;4:142ra94. [PMID: 22786679 DOI: 10.1126/scitranslmed.3003989] [Cited by in Crossref: 187] [Cited by in F6Publishing: 180] [Article Influence: 20.8] [Reference Citation Analysis]
204 Navarrete A, Armitage EG, Musteanu M, García A, Mastrangelo A, Bujak R, López-Casas PP, Hidalgo M, Barbas C. Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer. Pharmacol Res Perspect 2014;2:e00067. [PMID: 25505613 DOI: 10.1002/prp2.67] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
205 Kono T, Kondoh M, Kyuno D, Ito T, Kimura Y, Imamura M, Kohno T, Konno T, Furuhata T, Sawada N, Hirata K, Kojima T. Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. Pharmacol Res Perspect 2015;3:e00196. [PMID: 27022469 DOI: 10.1002/prp2.196] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
206 Sano M, Driscoll DR, DeJesus-Monge WE, Quattrochi B, Appleman VA, Ou J, Zhu LJ, Yoshida N, Yamazaki S, Takayama T, Sugitani M, Nemoto N, Klimstra DS, Lewis BC. Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61. Neoplasia 2016;18:785-94. [PMID: 27889647 DOI: 10.1016/j.neo.2016.11.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
207 Cirkel GA, Gadellaa-van Hooijdonk CG, Koudijs MJ, Willems SM, Voest EE. Tumor heterogeneity and personalized cancer medicine: are we being outnumbered? Future Oncol 2014;10:417-28. [PMID: 24559448 DOI: 10.2217/fon.13.214] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
208 Bhanot UK, Möller P. Mechanisms of parenchymal injury and signaling pathways in ectatic ducts of chronic pancreatitis: implications for pancreatic carcinogenesis. Lab Invest 2009;89:489-97. [DOI: 10.1038/labinvest.2009.19] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
209 Vu T, Davidson S, Borgesi J, Maksudul M, Jeon T, Shim J. Piecing together the puzzle: nanopore technology in detection and quantification of cancer biomarkers. RSC Adv 2017;7:42653-66. [DOI: 10.1039/c7ra08063h] [Cited by in Crossref: 11] [Article Influence: 2.2] [Reference Citation Analysis]
210 8 Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS. International network of cancer genome projects. Nature. 2010;464:993-998. [PMID: 20393554 DOI: 10.1038/nature08987] [Cited by in Crossref: 1489] [Cited by in F6Publishing: 1265] [Article Influence: 124.1] [Reference Citation Analysis]
211 Trask HW, Cowper-Sal-lari R, Sartor MA, Gui J, Heath CV, Renuka J, Higgins AJ, Andrews P, Korc M, Moore JH, Tomlinson CR. Microarray analysis of cytoplasmic versus whole cell RNA reveals a considerable number of missed and false positive mRNAs. RNA 2009;15:1917-28. [PMID: 19703940 DOI: 10.1261/rna.1677409] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
212 Heretsch P, Tzagkaroulaki L, Giannis A. Modulators of the hedgehog signaling pathway. Bioorg Med Chem 2010;18:6613-24. [PMID: 20708941 DOI: 10.1016/j.bmc.2010.07.038] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 7.7] [Reference Citation Analysis]
213 Shan Z, Shakoori A, Bodaghi S, Goldsmith P, Jin J, Wiest JS. TUSC1, a putative tumor suppressor gene, reduces tumor cell growth in vitro and tumor growth in vivo. PLoS One 2013;8:e66114. [PMID: 23776618 DOI: 10.1371/journal.pone.0066114] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
214 Dong H, Shim KN, Li JM, Estrema C, Ornelas TA, Nguyen F, Liu S, Ramamoorthy SL, Ho S, Carethers JM, Chow JY. Molecular mechanisms underlying Ca2+-mediated motility of human pancreatic duct cells. Am J Physiol Cell Physiol. 2010;299:C1493-C1503. [PMID: 20861471 DOI: 10.1152/ajpcell.00242.2010] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
215 Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 2016;22:278-87. [PMID: 26855150 DOI: 10.1038/nm.4038] [Cited by in Crossref: 127] [Cited by in F6Publishing: 105] [Article Influence: 21.2] [Reference Citation Analysis]
216 Tigan AS, Bellutti F, Kollmann K, Tebb G, Sexl V. CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene 2016;35:3083-91. [PMID: 26500059 DOI: 10.1038/onc.2015.407] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 10.9] [Reference Citation Analysis]
217 Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324:217. [PMID: 19264984 DOI: 10.1126/science.1171202] [Cited by in Crossref: 556] [Cited by in F6Publishing: 489] [Article Influence: 42.8] [Reference Citation Analysis]
218 Hruban RH, Klimstra DS, Zamboni G, Klöppel G. A semicentennial of pancreatic pathology: the genetic revolution is here, but don't throw the baby out with the bath water! Hum Pathol 2020;95:99-112. [PMID: 31521627 DOI: 10.1016/j.humpath.2019.08.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
219 Seufferlein T, Kleger A. Organoidomics - falling star or new galaxy in pancreatic cancer? Nat Rev Gastroenterol Hepatol 2018;15:586-7. [PMID: 30046146 DOI: 10.1038/s41575-018-0052-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
220 Sano M, Ijichi H, Takahashi R, Miyabayashi K, Fujiwara H, Yamada T, Kato H, Nakatsuka T, Tanaka Y, Tateishi K, Morishita Y, Moses HL, Isayama H, Koike K. Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment. Oncogenesis 2019;8:8. [PMID: 30659170 DOI: 10.1038/s41389-018-0117-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
221 Corbo V, Tortora G, Scarpa A. Molecular pathology of pancreatic cancer: from bench-to-bedside translation. Curr Drug Targets. 2012;13:744-752. [PMID: 22458520 DOI: 10.2174/138945012800564103] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
222 Taylor BS, Ladanyi M. Clinical cancer genomics: how soon is now? J Pathol 2011;223:319-27. [DOI: 10.1002/path.2794] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
223 Bagnyukova TV, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA, Astsaturov I. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents? Cancer Biol Ther 2010;10:839-53. [PMID: 20935499 DOI: 10.4161/cbt.10.9.13738] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
224 Pal A, Dziubinski M, Di Magliano MP, Simeone DM, Owens S, Thomas D, Peterson L, Potu H, Talpaz M, Donato NJ. Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth. Neoplasia 2018;20:152-64. [PMID: 29248719 DOI: 10.1016/j.neo.2017.11.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
225 Gao C, Chen G, Zhang DH, Zhang J, Kuan SF, Hu W, Esni F, Gao X, Guan JL, Chu E, Hu J. PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-CateninY654. Cell Mol Gastroenterol Hepatol 2019;8:561-78. [PMID: 31330317 DOI: 10.1016/j.jcmgh.2019.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
226 Wang H, Wang X, Xu L, Lin Y, Zhang J, Cao H. Identification of genomic alterations and associated transcriptomic profiling reveal the prognostic significance of MMP14 and PKM2 in patients with pancreatic cancer. Aging (Albany NY) 2020;12:18676-92. [PMID: 32950968 DOI: 10.18632/aging.103958] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
227 Zhang F, Zhong W, Li H, Huang K, Yu M, Liu Y. TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer. Front Cell Dev Biol 2021;9:665265. [PMID: 34124046 DOI: 10.3389/fcell.2021.665265] [Reference Citation Analysis]
228 Jiang J, Jia P, Zhao Z, Shen B. Key regulators in prostate cancer identified by co-expression module analysis. BMC Genomics 2014;15:1015. [PMID: 25418933 DOI: 10.1186/1471-2164-15-1015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
229 Orr B, Compton DA. A double-edged sword: how oncogenes and tumor suppressor genes can contribute to chromosomal instability. Front Oncol 2013;3:164. [PMID: 23825799 DOI: 10.3389/fonc.2013.00164] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
230 Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, Zhao L, Denley A. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol 2010;347:79-104. [PMID: 20582532 DOI: 10.1007/82_2010_80] [Cited by in Crossref: 28] [Cited by in F6Publishing: 49] [Article Influence: 2.5] [Reference Citation Analysis]
231 Parkin A, Man J, Timpson P, Pajic M. Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. FEBS J 2019;286:3510-39. [PMID: 31330086 DOI: 10.1111/febs.15011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
232 Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg 2013;257:17-26. [PMID: 22895395 DOI: 10.1097/SLA.0b013e31825ffbfb] [Cited by in Crossref: 120] [Cited by in F6Publishing: 64] [Article Influence: 13.3] [Reference Citation Analysis]
233 Pierobon M, Wulfkuhle J, Liotta LA, Petricoin Iii EF. Utilization of Proteomic Technologies for Precision Oncology Applications. Cancer Treat Res 2019;178:171-87. [PMID: 31209845 DOI: 10.1007/978-3-030-16391-4_6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
234 Albracht SP, Meijer AJ, Rydström J. Mammalian NADH:ubiquinone oxidoreductase (Complex I) and nicotinamide nucleotide transhydrogenase (Nnt) together regulate the mitochondrial production of H₂O₂--implications for their role in disease, especially cancer. J Bioenerg Biomembr 2011;43:541-64. [PMID: 21882037 DOI: 10.1007/s10863-011-9381-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
235 Martinelli P, Carrillo-de Santa Pau E, Cox T, Sainz B Jr, Dusetti N, Greenhalf W, Rinaldi L, Costello E, Ghaneh P, Malats N, Büchler M, Pajic M, Biankin AV, Iovanna J, Neoptolemos J, Real FX. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut 2017;66:1665-76. [PMID: 27325420 DOI: 10.1136/gutjnl-2015-311256] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 17.7] [Reference Citation Analysis]
236 Rettig EM, Talbot CC Jr, Sausen M, Jones S, Bishop JA, Wood LD, Tokheim C, Niknafs N, Karchin R, Fertig EJ, Wheelan SJ, Marchionni L, Considine M, Ling S, Fakhry C, Papadopoulos N, Kinzler KW, Vogelstein B, Ha PK, Agrawal N. Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. Cancer Prev Res (Phila) 2016;9:265-74. [PMID: 26862087 DOI: 10.1158/1940-6207.CAPR-15-0316] [Cited by in Crossref: 37] [Cited by in F6Publishing: 19] [Article Influence: 6.2] [Reference Citation Analysis]
237 Gu Y, Zhao W, Xia J, Zhang Y, Wu R, Wang C, Guo Z. Analysis of pathway mutation profiles highlights collaboration between cancer-associated superpathways. Hum Mutat 2011;32:1028-35. [PMID: 21618647 DOI: 10.1002/humu.21541] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
238 Thu KL, Radulovich N, Becker-Santos DD, Pikor LA, Pusic A, Lockwood WW, Lam WL, Tsao MS. SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/β-catenin signaling. Oncogene. 2014;33:279-288. [PMID: 23318427 DOI: 10.1038/onc.2012.595] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
239 Vandin F, Upfal E, Raphael BJ. Finding driver pathways in cancer: models and algorithms. Algorithms Mol Biol 2012;7:23. [PMID: 22954134 DOI: 10.1186/1748-7188-7-23] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
240 Polvani S, Tarocchi M, Tempesti S, Mello T, Ceni E, Buccoliero F, D'amico M, Boddi V, Farsi M, Nesi S, Nesi G, Milani S, Galli A. COUP-TFII in pancreatic adenocarcinoma: Clinical implication for patient survival and tumor progression: COUP-TFII and pancreatic cancer. Int J Cancer 2014;134:1648-58. [DOI: 10.1002/ijc.28502] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
241 Tew BY, Durand JK, Bryant KL, Hayes TK, Peng S, Tran NL, Gooden GC, Buckley DN, Der CJ, Baldwin AS, Salhia B. Genome-wide DNA methylation analysis of KRAS mutant cell lines. Sci Rep 2020;10:10149. [PMID: 32576853 DOI: 10.1038/s41598-020-66797-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
242 Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, Mohri D, Miyabayashi K, Asaoka Y, Maeda S. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest. 2011;121:4106-4117. [PMID: 21926469 DOI: 10.1172/jci42754] [Cited by in Crossref: 173] [Cited by in F6Publishing: 119] [Article Influence: 15.7] [Reference Citation Analysis]
243 Schmahl MJ, Regan DP, Rivers AC, Joesten WC, Kennedy MA. NMR-based metabolic profiling of urine, serum, fecal, and pancreatic tissue samples from the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer. PLoS One 2018;13:e0200658. [PMID: 30016349 DOI: 10.1371/journal.pone.0200658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
244 Maurer C, Holmstrom SR, He J, Laise P, Su T, Ahmed A, Hibshoosh H, Chabot JA, Oberstein PE, Sepulveda AR, Genkinger JM, Zhang J, Iuga AC, Bansal M, Califano A, Olive KP. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Gut 2019;68:1034-43. [PMID: 30658994 DOI: 10.1136/gutjnl-2018-317706] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 24.0] [Reference Citation Analysis]
245 Nolan-Stevaux O, Lau J, Truitt ML, Chu GC, Hebrok M, Fernández-Zapico ME, Hanahan D. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 2009;23:24-36. [PMID: 19136624 DOI: 10.1101/gad.1753809] [Cited by in Crossref: 285] [Cited by in F6Publishing: 267] [Article Influence: 21.9] [Reference Citation Analysis]
246 Naidoo N, Pawitan Y, Soong R, Cooper DN, Ku CS. Human genetics and genomics a decade after the release of the draft sequence of the human genome. Hum Genomics. 2011;5:577-622. [PMID: 22155605 DOI: 10.1186/1479-7364-5-6-577] [Cited by in Crossref: 65] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
247 van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 2014;14:121-134. [PMID: 24442140 DOI: 10.1038/nrc3647] [Cited by in Crossref: 233] [Cited by in F6Publishing: 209] [Article Influence: 29.1] [Reference Citation Analysis]
248 Halvey PJ, Ferrone CR, Liebler DC. GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples. J Proteome Res 2012;11:3908-13. [PMID: 22671702 DOI: 10.1021/pr300161j] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
249 An Y, Cai B, Chen J, Lv N, Yao J, Xue X, Tu M, Tang D, Wei J, Jiang K. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. Cancer Lett. 2013;329:228-235. [PMID: 23178452 DOI: 10.1016/j.canlet.2012.11.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
250 Carter H, Karchin R. Predicting the functional consequences of somatic missense mutations found in tumors. Methods Mol Biol 2014;1101:135-59. [PMID: 24233781 DOI: 10.1007/978-1-62703-721-1_8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
251 Eskander MF, Bliss LA, Tseng JF. Pancreatic adenocarcinoma. Current Problems in Surgery 2016;53:107-54. [DOI: 10.1067/j.cpsurg.2016.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
252 Mardis ER. Applying next-generation sequencing to pancreatic cancer treatment. Nat Rev Gastroenterol Hepatol 2012;9:477-86. [PMID: 22751458 DOI: 10.1038/nrgastro.2012.126] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
253 Baudot A, Real FX, Izarzugaza JM, Valencia A. From cancer genomes to cancer models: bridging the gaps. EMBO Rep 2009;10:359-66. [PMID: 19305388 DOI: 10.1038/embor.2009.46] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
254 Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
255 Subbarayan PR, Sarkar M, Nagaraja Rao S, Philip S, Kumar P, Altman N, Reis I, Ahmed M, Ardalan B, Lokeshwar BL. Achyranthes aspera (Apamarg) leaf extract inhibits human pancreatic tumor growth in athymic mice by apoptosis. Journal of Ethnopharmacology 2012;142:523-30. [DOI: 10.1016/j.jep.2012.05.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
256 Pan H, Diao H, Zhong W, Wang T, Wen P, Wu C. A Cancer Cell Cluster Marked by LincRNA MEG3 Leads Pancreatic Ductal Adenocarcinoma Metastasis. Front Oncol 2021;11:656564. [PMID: 34055623 DOI: 10.3389/fonc.2021.656564] [Reference Citation Analysis]
257 Chandana S, Babiker HM, Mahadevan D. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). Expert Opinion on Investigational Drugs 2018;28:161-77. [DOI: 10.1080/13543784.2019.1557145] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
258 Bernard V, Semaan A, Huang J, San Lucas FA, Mulu FC, Stephens BM, Guerrero PA, Huang Y, Zhao J, Kamyabi N, Sen S, Scheet PA, Taniguchi CM, Kim MP, Tzeng CW, Katz MH, Singhi AD, Maitra A, Alvarez HA. Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. Clin Cancer Res 2019;25:2194-205. [PMID: 30385653 DOI: 10.1158/1078-0432.CCR-18-1955] [Cited by in Crossref: 98] [Cited by in F6Publishing: 75] [Article Influence: 24.5] [Reference Citation Analysis]
259 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 672] [Article Influence: 75.6] [Reference Citation Analysis]
260 Wood LD, Yurgelun MB, Goggins MG. Genetics of Familial and Sporadic Pancreatic Cancer. Gastroenterology 2019;156:2041-55. [PMID: 30660730 DOI: 10.1053/j.gastro.2018.12.039] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
261 Zhang W, Tan B, Deng J, Haitao Z. Multiomics analysis of soybean meal induced marine fish enteritis in juvenile pearl gentian grouper, Epinephelus fuscoguttatus ♀ × Epinephelus lanceolatus ♂. Sci Rep 2021;11:23319. [PMID: 34857775 DOI: 10.1038/s41598-021-02278-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
262 Shahda S, Timms KM, Ibrahim AA, Reid JE, Cramer HM, Radovich M, Ibrahim S, Allen B, O’neil BH. Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy. JCO Precision Oncology 2018. [DOI: 10.1200/po.17.00087] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
263 Pham VVH, Liu L, Bracken CP, Goodall GJ, Long Q, Li J, Le TD. CBNA: A control theory based method for identifying coding and non-coding cancer drivers. PLoS Comput Biol 2019;15:e1007538. [PMID: 31790386 DOI: 10.1371/journal.pcbi.1007538] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
264 Matsuoka T, Yashiro M. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. World J Gastroenterol 2016; 22(2): 776-789 [PMID: 26811624 DOI: 10.3748/wjg.v22.i2.776] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
265 Tomaszewski MR, Dominguez-Viqueira W, Ortiz A, Shi Y, Costello JR, Enderling H, Rosenberg SA, Gillies RJ. Heterogeneity analysis of MRI T2 maps for measurement of early tumor response to radiotherapy. NMR Biomed 2021;34:e4454. [PMID: 33325086 DOI: 10.1002/nbm.4454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
266 Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med. 2012;6:597-612. [PMID: 23075238 DOI: 10.2217/bmm.12.69] [Cited by in Crossref: 118] [Cited by in F6Publishing: 107] [Article Influence: 13.1] [Reference Citation Analysis]
267 Teng H, Wang H, Chen W, Chao T, Hsieh Y, Hsih C, Tzeng C, Chen PC, Yen C. Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma: EGFR Pathway Markers in Synovial Sarcoma. J Surg Oncol 2011;103:773-81. [DOI: 10.1002/jso.21852] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
268 Sahlin M, Bauden MP, Andersson R, Ansari D. Radioimmunotherapy--a potential novel tool for pancreatic cancer therapy? Tumour Biol 2015;36:4053-62. [PMID: 25926382 DOI: 10.1007/s13277-015-3479-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
269 Mao F, Li D, Xin Z, Du Y, Wang X, Xu P, Li Z, Qian J, Yao J. High Expression of COL17A1 Predicts Poor Prognosis and Promotes the Tumor Progression via NF-κB Pathway in Pancreatic Adenocarcinoma. J Oncol 2020;2020:8868245. [PMID: 33381179 DOI: 10.1155/2020/8868245] [Reference Citation Analysis]
270 de Souza SJ, Stransky B, Camargo AA. Insights into gliomagenesis: systems biology unravels key pathways. Genome Med 2009;1:101. [PMID: 19863775 DOI: 10.1186/gm101] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
271 Duesberg P, Iacobuzio-Donahue C, Brosnan JA, McCormack A, Mandrioli D, Chen L. Origin of metastases: subspecies of cancers generated by intrinsic karyotypic variations. Cell Cycle 2012;11:1151-66. [PMID: 22377695 DOI: 10.4161/cc.11.6.19580] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
272 Connor AA, Denroche RE, Jang GH, Lemire M, Zhang A, Chan-Seng-Yue M, Wilson G, Grant RC, Merico D, Lungu I, Bartlett JMS, Chadwick D, Liang SB, Eagles J, Mbabaali F, Miller JK, Krzyzanowski P, Armstrong H, Luo X, Jorgensen LGT, Romero JM, Bavi P, Fischer SE, Serra S, Hafezi-Bakhtiari S, Caglar D, Roehrl MHA, Cleary S, Hollingsworth MA, Petersen GM, Thayer S, Law CHL, Nanji S, Golan T, Smith AL, Borgida A, Dodd A, Hedley D, Wouters BG, O'Kane GM, Wilson JM, Zogopoulos G, Notta F, Knox JJ, Gallinger S. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Cancer Cell 2019;35:267-282.e7. [PMID: 30686769 DOI: 10.1016/j.ccell.2018.12.010] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 19.3] [Reference Citation Analysis]
273 Cui R, Yang L, Wang Y, Zhong M, Yu M, Chen B. Elevated Expression of ASXL2 is Associated with Poor Prognosis in Colorectal Cancer by Enhancing Tumorigenesis and Inducing Cell Proliferation. Cancer Manag Res 2020;12:10221-8. [PMID: 33116876 DOI: 10.2147/CMAR.S266083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
274 Munding JB, Adai AT, Maghnouj A, Urbanik A, Zöllner H, Liffers ST, Chromik AM, Uhl W, Szafranska-Schwarzbach AE, Tannapfel A, Hahn SA. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int J Cancer 2012;131:E86-95. [PMID: 21953293 DOI: 10.1002/ijc.26466] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 6.7] [Reference Citation Analysis]
275 Tan DS, Gerlinger M, Teh B, Swanton C. Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. European Journal of Cancer 2010;46:2166-77. [DOI: 10.1016/j.ejca.2010.03.019] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 4.9] [Reference Citation Analysis]
276 Guo J, Gao J, Li Z, Gong Y, Man X, Jin J, Wu H. Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo. Cancer Lett. 2013;339:185-194. [PMID: 23791879 DOI: 10.1016/j.canlet.2013.06.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
277 Preston CC, Faustino RS. Nuclear Envelope Regulation of Oncogenic Processes: Roles in Pancreatic Cancer. Epigenomes 2018;2:15. [PMID: 31867128 DOI: 10.3390/epigenomes2030015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
278 Reiter JG, Bozic I, Allen B, Chatterjee K, Nowak MA. The effect of one additional driver mutation on tumor progression. Evol Appl 2013;6:34-45. [PMID: 23396615 DOI: 10.1111/eva.12020] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
279 Lizardi PM, Forloni M, Wajapeyee N. Genome-wide approaches for cancer gene discovery. Trends Biotechnol 2011;29:558-68. [PMID: 21757246 DOI: 10.1016/j.tibtech.2011.06.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
280 Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, Sporn MB. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res (Phila) 2010;3:1427-34. [PMID: 20959520 DOI: 10.1158/1940-6207.CAPR-10-0197] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
281 Northcott PA, Rutka JT, Taylor MD. Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. FOC 2010;28:E6. [DOI: 10.3171/2009.10.focus09218] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
282 Nagai M, Sho M, Akahori T, Nakagawa K, Nakamura K. Application of liquid biopsy for surgical management of pancreatic cancer. Ann Gastroenterol Surg 2020;4:216-23. [PMID: 32490335 DOI: 10.1002/ags3.12317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
283 Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K, Gisselsson D, Øra I, Speleman F, Caron HN, Versteeg R. Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer 2012;51:10-9. [PMID: 22034077 DOI: 10.1002/gcc.20926] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
284 Westwick JK, Lamerdin JE. Improving Drug Discovery with Contextual Assays and Cellular Systems Analysis. In: Luttrell LM, Ferguson SSG, editors. Signal Transduction Protocols. Totowa: Humana Press; 2011. pp. 61-73. [DOI: 10.1007/978-1-61779-160-4_3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
285 Vandin F, Upfal E, Raphael BJ. Algorithms for detecting significantly mutated pathways in cancer. J Comput Biol 2011;18:507-22. [PMID: 21385051 DOI: 10.1089/cmb.2010.0265] [Cited by in Crossref: 276] [Cited by in F6Publishing: 214] [Article Influence: 25.1] [Reference Citation Analysis]
286 Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology 2019;156:2242-2253.e4. [DOI: 10.1053/j.gastro.2019.02.037] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 27.0] [Reference Citation Analysis]
287 Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73-85. [PMID: 26830752 DOI: 10.1016/s0140-6736(16)00141-0] [Cited by in Crossref: 995] [Cited by in F6Publishing: 643] [Article Influence: 165.8] [Reference Citation Analysis]
288 Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019;68:742-58. [PMID: 30396902 DOI: 10.1136/gutjnl-2018-316822] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
289 Wei W, Sun Z, da Silveira WA, Yu Z, Lawson A, Hardiman G, Kelemen LE, Chung D. Semi-supervised identification of cancer subgroups using survival outcomes and overlapping grouping information. Stat Methods Med Res 2019;28:2137-49. [PMID: 29336210 DOI: 10.1177/0962280217752980] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
290 Dong X, Li Y, Hess KR, Abbruzzese JL, Li D. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist. 2011;16:61-70. [PMID: 21212431 DOI: 10.1634/theoncologist.2010-0127] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
291 Grant TJ, Hua K, Singh A. Molecular Pathogenesis of Pancreatic Cancer. Prog Mol Biol Transl Sci. 2016;144:241-275. [PMID: 27865459 DOI: 10.1016/bs.pmbts.2016.09.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
292 Binder MJ, McCoombe S, Williams ED, McCulloch DR, Ward AC. The extracellular matrix in cancer progression: Role of hyalectan proteoglycans and ADAMTS enzymes. Cancer Lett 2017;385:55-64. [PMID: 27838414 DOI: 10.1016/j.canlet.2016.11.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
293 Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N;  Australian Pancreatic Cancer Genome Initiative; Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399-405. [PMID: 23103869 DOI: 10.1038/nature11547] [Cited by in Crossref: 1267] [Cited by in F6Publishing: 1169] [Article Influence: 126.7] [Reference Citation Analysis]
294 Wang QJ, Yu Z, Griffith K, Hanada K, Restifo NP, Yang JC. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunol Res. 2016;4:204-214. [PMID: 26701267 DOI: 10.1158/2326-6066.cir-15-0188] [Cited by in Crossref: 86] [Cited by in F6Publishing: 62] [Article Influence: 12.3] [Reference Citation Analysis]
295 Chen SH, Hung WC, Wang P, Paul C, Konstantopoulos K. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep 2013;3:1870. [PMID: 23694968 DOI: 10.1038/srep01870] [Cited by in Crossref: 96] [Cited by in F6Publishing: 99] [Article Influence: 10.7] [Reference Citation Analysis]
296 Karslioglu E, Kleinberger JW, Salim FG, Cox AE, Takane KK, Scott DK, Stewart AF. cMyc is a principal upstream driver of beta-cell proliferation in rat insulinoma cell lines and is an effective mediator of human beta-cell replication. Mol Endocrinol 2011;25:1760-72. [PMID: 21885567 DOI: 10.1210/me.2011-1074] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
297 Kim HS, Sung YJ, Paik S. Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine. Yonsei Med J 2015;56:1186-98. [PMID: 26256959 DOI: 10.3349/ymj.2015.56.5.1186] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
298 Küntzer J, Eggle D, Klostermann S, Burtscher H. Human variation databases. Database (Oxford) 2010;2010:baq015. [PMID: 20639550 DOI: 10.1093/database/baq015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
299 Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022. [PMID: 27158978 DOI: 10.1038/nrdp.2016.22] [Cited by in Crossref: 657] [Cited by in F6Publishing: 617] [Article Influence: 109.5] [Reference Citation Analysis]
300 Abel EV, Kim EJ, Wu J, Hynes M, Bednar F, Proctor E, Wang L, Dziubinski ML, Simeone DM. The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. PLoS One 2014;9:e91983. [PMID: 24647545 DOI: 10.1371/journal.pone.0091983] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 11.9] [Reference Citation Analysis]
301 Sorber R, Teper Y, Abisoye-Ogunniyan A, Waterfall JJ, Davis S, Killian JK, Pineda M, Ray S, McCord MR, Pflicke H, Burkett SS, Meltzer PS, Rudloff U. Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion. PLoS One 2016;11:e0149833. [PMID: 26962861 DOI: 10.1371/journal.pone.0149833] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
302 Lanfredini S, Thapa A, O'Neill E. RAS in pancreatic cancer. Biochem Soc Trans 2019;47:961-72. [PMID: 31341034 DOI: 10.1042/BST20170521] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
303 Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH, Goggins M. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Mod Pathol. 2011;24:1237-1247. [PMID: 21552209 DOI: 10.1038/modpathol.2011.74] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
304 Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL, Hruban RH. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res. 2012;18:4257-4265. [PMID: 22896692 DOI: 10.1158/1078-0432.ccr-12-0315] [Cited by in Crossref: 85] [Cited by in F6Publishing: 53] [Article Influence: 9.4] [Reference Citation Analysis]
305 Sekita-Hatakeyama Y, Nishikawa T, Takeuchi M, Morita K, Takeda M, Hatakeyama K, Nakai T, Uchiyama T, Itami H, Fujii T, Mitoro A, Sho M, Ohbayashi C. K-ras mutation analysis of residual liquid-based cytology specimens from endoscopic ultrasound-guided fine needle aspiration improves cell block diagnosis of pancreatic ductal adenocarcinoma. PLoS One 2018;13:e0193692. [PMID: 29494669 DOI: 10.1371/journal.pone.0193692] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
306 Arensman MD, Nguyen P, Kershaw KM, Lay AR, Ostertag-Hill CA, Sherman MH, Downes M, Liddle C, Evans RM, Dawson DW. Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer. Mol Cancer Res. 2015;13:1509-1519. [PMID: 26224368 DOI: 10.1158/1541-7786.mcr-15-0204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
307 Kishikawa T, Otsuka M, Yoshikawa T, Ohno M, Ijichi H, Koike K. Satellite RNAs promote pancreatic oncogenic processes via the dysfunction of YBX1. Nat Commun 2016;7:13006. [PMID: 27667193 DOI: 10.1038/ncomms13006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
308 Oldfield LE, Connor AA, Gallinger S. Molecular Events in the Natural History of Pancreatic Cancer. Trends Cancer 2017;3:336-46. [PMID: 28718411 DOI: 10.1016/j.trecan.2017.04.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
309 Lee DJ, Schönleben F, Banuchi VE, Qiu W, Close LG, Assaad AM, Su GH. Multiple tumor-suppressor genes on chromosome 3p contribute to head and neck squamous cell carcinoma tumorigenesis. Cancer Biol Ther 2010;10:689-93. [PMID: 20657180 DOI: 10.4161/cbt.10.7.12886] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
310 McIntyre RE, van der Weyden L, Adams DJ. Cancer gene discovery in the mouse. Curr Opin Genet Dev. 2012;22:14-20. [PMID: 22265936 DOI: 10.1016/j.gde.2011.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
311 Ziogas DE, Roukos DH. Limitations of Isolated Tumor Cells in Gastric Cancer: Heterogeneity Requests Systems Biology Approaches Towards Personalized Medicine. Ann Surg Oncol 2010;17:343-4. [DOI: 10.1245/s10434-009-0747-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
312 Bayraktar S, Rocha-lima CM. Advanced or Metastatic Pancreatic Cancer: Molecular Targeted Therapies: S. B AYRAKTAR AND C. M. R OCHA -L IMA : A DVANCED OR M ETASTATIC P ANCREATIC C ANCER. Mt Sinai J Med 2010;77:606-19. [DOI: 10.1002/msj.20217] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
313 Hruban RH, Iacobuzio-donahue C. The Pancreas. Robbins and Cotran Pathologic Basis of Disease. Elsevier; 2010. pp. 891-904. [DOI: 10.1016/b978-1-4377-0792-2.50024-9] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
314 Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, Dralle H, Toledo SP, Toledo RA, Morris LG, Ghossein RA, Fagin JA, Chan TA, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Nelkin BD, Ball DW. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013;98:E364-9. [PMID: 23264394 DOI: 10.1210/jc.2012-2703] [Cited by in Crossref: 133] [Cited by in F6Publishing: 122] [Article Influence: 13.3] [Reference Citation Analysis]
315 Huang S, Ernberg I, Kauffman S. Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Semin Cell Dev Biol 2009;20:869-76. [PMID: 19595782 DOI: 10.1016/j.semcdb.2009.07.003] [Cited by in Crossref: 312] [Cited by in F6Publishing: 243] [Article Influence: 24.0] [Reference Citation Analysis]
316 Shih IeM, Panuganti PK, Kuo KT, Mao TL, Kuhn E, Jones S, Velculescu VE, Kurman RJ, Wang TL. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol 2011;178:1442-7. [PMID: 21435433 DOI: 10.1016/j.ajpath.2011.01.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 6.1] [Reference Citation Analysis]
317 Krem MM, Salipante SJ, Horwitz MS. Mutations in a gene encoding a midbody protein in binucleated Reed-Sternberg cells of Hodgkin lymphoma. Cell Cycle 2010;9:670-5. [PMID: 20107318 DOI: 10.4161/cc.9.4.10780] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
318 Goya R, Sun MG, Morin RD, Leung G, Ha G, Wiegand KC, Senz J, Crisan A, Marra MA, Hirst M, Huntsman D, Murphy KP, Aparicio S, Shah SP. SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics 2010;26:730-6. [PMID: 20130035 DOI: 10.1093/bioinformatics/btq040] [Cited by in Crossref: 159] [Cited by in F6Publishing: 143] [Article Influence: 13.3] [Reference Citation Analysis]
319 Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, Purushotham AD, Naredi P, Eggermont A, Brennan MF, Steinberg ML, De Ridder M, McCloskey SA, Verellen D, Roberts T, Storme G, Hicks RJ, Ell PJ, Hirsch BR, Carbone DP, Schulman KA, Catchpole P, Taylor D, Geissler J, Brinker NG, Meltzer D, Kerr D, Aapro M. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12:933-80. [PMID: 21958503 DOI: 10.1016/S1470-2045(11)70141-3] [Cited by in Crossref: 441] [Cited by in F6Publishing: 146] [Article Influence: 40.1] [Reference Citation Analysis]
320 Ellsworth KA, Eckloff BW, Li L, Moon I, Fridley BL, Jenkins GD, Carlson E, Brisbin A, Abo R, Bamlet W, Petersen G, Wieben ED, Wang L. Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma. PLoS One 2013;8:e70216. [PMID: 23936393 DOI: 10.1371/journal.pone.0070216] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
321 Li C, Yu H, Sun Y, Zeng X, Zhang W. Identification of the hub genes in gastric cancer through weighted gene co-expression network analysis. PeerJ. 2021;9:e10682. [PMID: 33717664 DOI: 10.7717/peerj.10682] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
322 Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, Kato S, Kurzrock R. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019;12:130. [PMID: 31801585 DOI: 10.1186/s13045-019-0824-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
323 Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer 2020;19:49. [PMID: 32122376 DOI: 10.1186/s12943-020-01167-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 20.0] [Reference Citation Analysis]
324 Pan T, Zhang Y, Zhou N, He X, Chen C, Liang L, Duan X, Lin Y, Wu K, Zhang H. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth. Oncotarget 2016;7:44299-309. [PMID: 27322423 DOI: 10.18632/oncotarget.9996] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
325 Cook N, Hansen AR, Siu LL, Abdul Razak AR. Early phase clinical trials to identify optimal dosing and safety. Mol Oncol 2015;9:997-1007. [PMID: 25160636 DOI: 10.1016/j.molonc.2014.07.025] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 5.9] [Reference Citation Analysis]
326 Merchant AA, Matsui W. Targeting Hedgehog--a cancer stem cell pathway. Clin Cancer Res. 2010;16:3130-3140. [PMID: 20530699 DOI: 10.1158/1078-0432.ccr-09-2846] [Cited by in Crossref: 321] [Cited by in F6Publishing: 186] [Article Influence: 26.8] [Reference Citation Analysis]
327 Bernard V, Fleming J, Maitra A. Molecular and Genetic Basis of Pancreatic Carcinogenesis. Surgical Oncology Clinics of North America 2016;25:227-38. [DOI: 10.1016/j.soc.2015.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
328 Mayer RJ, Venook AP, Schilsky RL. Progress against GI cancer during the American Society of Clinical Oncology’s first 50 years. J Clin Oncol. 2014;32:1521-1530. [PMID: 24752046 DOI: 10.1200/jco.2014.55.4121] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
329 Kashiwagi H, McDunn JE, Simon PO Jr, Goedegebuure PS, Vangveravong S, Chang K, Hotchkiss RS, Mach RH, Hawkins WG. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J Transl Med 2009;7:24. [PMID: 19323815 DOI: 10.1186/1479-5876-7-24] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
330 Bauer-Mehren A, Bundschus M, Rautschka M, Mayer MA, Sanz F, Furlong LI. Gene-disease network analysis reveals functional modules in mendelian, complex and environmental diseases. PLoS One. 2011;6:e20284. [PMID: 21695124 DOI: 10.1371/journal.pone.0020284] [Cited by in Crossref: 109] [Cited by in F6Publishing: 85] [Article Influence: 9.9] [Reference Citation Analysis]
331 Roberts NJ, Klein AP. Genome-wide sequencing to identify the cause of hereditary cancer syndromes: with examples from familial pancreatic cancer. Cancer Lett 2013;340:227-33. [PMID: 23196058 DOI: 10.1016/j.canlet.2012.11.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
332 Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog 2013;18:43-73. [PMID: 23237552 DOI: 10.1615/critrevoncog.v18.i1-2.40] [Cited by in Crossref: 401] [Cited by in F6Publishing: 257] [Article Influence: 44.6] [Reference Citation Analysis]
333 Hang Y, Tang S, Tang W, Větvička D, Zhang C, Xie Y, Yu F, Yu A, Sil D, Li J, Singh RK, Oupický D. Polycation fluorination improves intraperitoneal siRNA delivery in metastatic pancreatic cancer. J Control Release 2021;333:139-50. [PMID: 33774121 DOI: 10.1016/j.jconrel.2021.03.028] [Reference Citation Analysis]
334 Gerstung M, Beerenwinkel N. Waiting Time Models of Cancer Progression. Mathematical Population Studies 2010;17:115-35. [DOI: 10.1080/08898480.2010.490994] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
335 Furlong LI. Human diseases through the lens of network biology. Trends in Genetics 2013;29:150-9. [DOI: 10.1016/j.tig.2012.11.004] [Cited by in Crossref: 126] [Cited by in F6Publishing: 111] [Article Influence: 14.0] [Reference Citation Analysis]
336 von Burstin J, Diersch S, Schneider G, Reichert M, Rustgi AK, Schmid RM. Detection of Tumor Suppressor Genes in Cancer Development by a Novel shRNA-Based Method. Mol Cancer Res 2015;13:863-9. [PMID: 25724428 DOI: 10.1158/1541-7786.MCR-14-0709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
337 Wong HH, Lemoine NR. Novel therapies for pancreatic cancer: setbacks and progress. Future Oncol 2010;6:1061-4. [PMID: 20624116 DOI: 10.2217/fon.10.70] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
338 Polireddy K, Chen Q. Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. J Cancer 2016;7:1497-514. [PMID: 27471566 DOI: 10.7150/jca.14922] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
339 Erkan M, Kurtoglu M, Kleeff J. The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev Gastroenterol Hepatol 2016;10:301-16. [PMID: 26560854 DOI: 10.1586/17474124.2016.1117386] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 9.4] [Reference Citation Analysis]
340 Rikiishi H. Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors. Cancers (Basel) 2010;2:2026-43. [PMID: 24281216 DOI: 10.3390/cancers2042026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
341 Chick JM, Kolippakkam D, Nusinow DP, Zhai B, Rad R, Huttlin EL, Gygi SP. A mass-tolerant database search identifies a large proportion of unassigned spectra in shotgun proteomics as modified peptides. Nat Biotechnol 2015;33:743-9. [PMID: 26076430 DOI: 10.1038/nbt.3267] [Cited by in Crossref: 245] [Cited by in F6Publishing: 196] [Article Influence: 35.0] [Reference Citation Analysis]
342 Wang T, Zhou M, Zhang Q, Zhang C, Peng G. ubtor Mutation Causes Motor Hyperactivity by Activating mTOR Signaling in Zebrafish. Neurosci Bull 2021. [PMID: 34309811 DOI: 10.1007/s12264-021-00755-z] [Reference Citation Analysis]
343 Mallya K, Haridas D, Seshacharyulu P, Pothuraju R, Junker WM, Krishn SR, Muniyan S, Vengoji R, Batra SK, Rachagani S. Acinar transformed ductal cells exhibit differential mucin expression in a tamoxifen-induced pancreatic ductal adenocarcinoma mouse model. Biol Open 2020;9:bio052878. [PMID: 32709695 DOI: 10.1242/bio.052878] [Reference Citation Analysis]
344 Zhang SQ, Catenacci DV. How can next-generation diagnostics aid pancreatic adenocarcinoma treatment? Future Oncology 2016;12:585-8. [DOI: 10.2217/fon.15.353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
345 Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009;4:1670-1680. [PMID: 19876027 DOI: 10.1038/nprot.2009.171] [Cited by in Crossref: 244] [Cited by in F6Publishing: 229] [Article Influence: 18.8] [Reference Citation Analysis]
346 Yee NS. Zebrafish as a Biological System for Identifying and Validating Therapeutic Targets and Compounds. In: Han H, Grippo P, editors. Drug Discovery in Pancreatic Cancer. New York: Springer; 2010. pp. 95-112. [DOI: 10.1007/978-1-4419-1160-5_5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
347 Pajkos M, Mészáros B, Simon I, Dosztányi Z. Is there a biological cost of protein disorder? Analysis of cancer-associated mutations. Mol Biosyst 2012;8:296-307. [PMID: 21918772 DOI: 10.1039/c1mb05246b] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
348 Mathew E, Brannon AL, Del Vecchio A, Garcia PE, Penny MK, Kane KT, Vinta A, Buckanovich RJ, di Magliano MP. Mesenchymal Stem Cells Promote Pancreatic Tumor Growth by Inducing Alternative Polarization of Macrophages. Neoplasia. 2016;18:142-151. [PMID: 26992915 DOI: 10.1016/j.neo.2016.01.005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 9.7] [Reference Citation Analysis]
349 Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331:435-439. [PMID: 21163964 DOI: 10.1126/science.1198056] [Cited by in Crossref: 529] [Cited by in F6Publishing: 492] [Article Influence: 44.1] [Reference Citation Analysis]
350 Rahnamay Farnood P, Danesh Pazhooh R, Asemi Z, Yousefi B. DNA damage response and repair in pancreatic cancer development and therapy. DNA Repair (Amst) 2021;103:103116. [PMID: 33882393 DOI: 10.1016/j.dnarep.2021.103116] [Reference Citation Analysis]
351 Pilarsky C, Grutzmann R. Genomics of pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int 2014;13:381-5. [PMID: 25100122 DOI: 10.1016/s1499-3872(14)60281-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
352 Nielsen AY, Gjerstorff MF. Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic Instability. Int J Mol Sci 2016;17:E890. [PMID: 27275820 DOI: 10.3390/ijms17060890] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
353 Duffy A, Kummar S. Metastatic pancreatic adenocarcinoma: current standards, future directions. Am J Ther 2010;17:79-85. [PMID: 19636248 DOI: 10.1097/MJT.0b013e31819dc8ed] [Reference Citation Analysis]
354 Kramer-Marek G, Gore J, Korc M. Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions. Cancer Lett 2013;341:132-8. [PMID: 23941833 DOI: 10.1016/j.canlet.2013.08.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
355 Gough NR, Xiang X, Mishra L. TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer. Gastroenterology 2021;161:434-452.e15. [PMID: 33940008 DOI: 10.1053/j.gastro.2021.04.064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
356 Zhu T, Gao YF, Chen YX, Wang ZB, Yin JY, Mao XY, Li X, Zhang W, Zhou HH, Liu ZQ. Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer. Oncotarget 2017;8:21281-9. [PMID: 28177904 DOI: 10.18632/oncotarget.15068] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
357 Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kawasaki Y, Arigami T, Mori S, Kijima Y, Ueno S, Shinchi H, Natsugoe S. A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence. Pancreas 2018;47:753-8. [PMID: 29771771 DOI: 10.1097/MPA.0000000000001066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
358 Miller MS, Allen P, Brentnall TA, Goggins M, Hruban RH, Petersen GM, Rao CV, Whitcomb DC, Brand RE, Chari ST, Klein AP, Lubman DM, Rhim AD, Simeone DM, Wolpin BM, Umar A, Srivastava S, Steele VE, Rinaudo JA. Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report. Pancreas. 2016;45:1080-1091. [PMID: 27518363 DOI: 10.1097/mpa.0000000000000705] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
359 Dembinski JL, Krauss S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis 2009;26:611-23. [PMID: 19421880 DOI: 10.1007/s10585-009-9260-0] [Cited by in Crossref: 168] [Cited by in F6Publishing: 159] [Article Influence: 12.9] [Reference Citation Analysis]
360 Omura N, Griffith M, Vincent A, Li A, Hong SM, Walter K, Borges M, Goggins M. Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins. Mol Cancer Res 2010;8:821-32. [PMID: 20530583 DOI: 10.1158/1541-7786.MCR-09-0336] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
361 Glassman DC, Palmaira RL, Covington CM, Desai AM, Ku GY, Li J, Harding JJ, Varghese AM, O'Reilly EM, Yu KH. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer 2018;18:693. [PMID: 29945562 DOI: 10.1186/s12885-018-4605-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
362 Takano S, Fukasawa M, Kadokura M, Shindo H, Takahashi E, Hirose S, Fukasawa Y, Kawakami S, Hayakawa H, Maekawa S, Mochizuki K, Kawaida H, Kono H, Itakura J, Sato T, Ichikawa D, Enomoto N. Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer. Pancreas 2019;48:1032-40. [DOI: 10.1097/mpa.0000000000001371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
363 Schreiber TH, Deyev VV, Rosenblatt JD, Podack ER. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res 2009;69:2026-33. [PMID: 19223534 DOI: 10.1158/0008-5472.CAN-08-3706] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
364 Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol. 2009;1:a003129. [PMID: 20457567 DOI: 10.1101/cshperspect.a003129] [Cited by in Crossref: 391] [Cited by in F6Publishing: 396] [Article Influence: 30.1] [Reference Citation Analysis]
365 Shouksmith AE, Shah F, Grimard ML, Gawel JM, Raouf YS, Geletu M, Berger-Becvar A, de Araujo ED, Luchman HA, Heaton WL, Bakhshinyan D, Adile AA, Venugopal C, O'Hare T, Deininger MW, Singh SK, Konieczny SF, Weiss S, Fishel ML, Gunning PT. Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. J Med Chem 2019;62:2651-65. [PMID: 30776234 DOI: 10.1021/acs.jmedchem.8b01957] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
366 Chen G, Mosier S, Gocke CD, Lin MT, Eshleman JR. Cytosine deamination is a major cause of baseline noise in next-generation sequencing. Mol Diagn Ther 2014;18:587-93. [PMID: 25091469 DOI: 10.1007/s40291-014-0115-2] [Cited by in Crossref: 88] [Cited by in F6Publishing: 69] [Article Influence: 12.6] [Reference Citation Analysis]
367 Stites EC, Shaw AS. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors. CPT Pharmacometrics Syst Pharmacol 2018;7:342-51. [PMID: 29484842 DOI: 10.1002/psp4.12291] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
368 Monkman JH, Thompson EW, Nagaraj SH. Targeting Epithelial Mesenchymal Plasticity in Pancreatic Cancer: A Compendium of Preclinical Discovery in a Heterogeneous Disease. Cancers (Basel) 2019;11:E1745. [PMID: 31703358 DOI: 10.3390/cancers11111745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
369 Ali H, Urolagin S, Gurarslan Ö, Vihinen M. Performance of Protein Disorder Prediction Programs on Amino Acid Substitutions: HUMAN MUTATION. Human Mutation 2014;35:794-804. [DOI: 10.1002/humu.22564] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
370 Bell J. Redefining disease. Clin Med (Lond) 2010;10:584-94. [PMID: 21413484 DOI: 10.7861/clinmedicine.10-6-584] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
371 Qin C, Yang G, Yang J, Ren B, Wang H, Chen G, Zhao F, You L, Wang W, Zhao Y. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer 2020;19:50. [PMID: 32122374 DOI: 10.1186/s12943-020-01169-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
372 Herbst B, Zheng L. Precision medicine in pancreatic cancer: treating every patient as an exception. The Lancet Gastroenterology & Hepatology 2019;4:805-10. [DOI: 10.1016/s2468-1253(19)30175-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
373 Veenstra VL, Garcia-Garijo A, van Laarhoven HW, Bijlsma MF. Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer. Cancers (Basel) 2018;10:E34. [PMID: 29382042 DOI: 10.3390/cancers10020034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
374 Robert F, Pelletier J. Translation initiation: a critical signalling node in cancer. Expert Opin Ther Targets 2009;13:1279-93. [PMID: 19705976 DOI: 10.1517/14728220903241625] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
375 Van Laethem JL, Verslype C, Iovanna JL, Michl P, Conroy T, Louvet C, Hammel P, Mitry E, Ducreux M, Maraculla T. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol. 2012;23:570-576. [PMID: 21810728 DOI: 10.1093/annonc/mdr351] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
376 Kanteti R, Batra SK, Lennon FE, Salgia R. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget 2016;7:31586-601. [PMID: 26980710 DOI: 10.18632/oncotarget.8040] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
377 Brock RM, Beitel-White N, Coutermarsh-Ott S, Grider DJ, Lorenzo MF, Ringel-Scaia VM, Manuchehrabadi N, Martin RCG, Davalos RV, Allen IC. Patient Derived Xenografts Expand Human Primary Pancreatic Tumor Tissue Availability for ex vivo Irreversible Electroporation Testing. Front Oncol 2020;10:843. [PMID: 32528898 DOI: 10.3389/fonc.2020.00843] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
378 Zhou Y, Huang J, Yu X, Jiang X, Shi Y, Weng Y, Kuai Y, Lei L, Ren G, Feng X, Zhong G, Liu Q, Pan H, Zhang X, Zhou R, Lu C. LITAF is a potential tumor suppressor in pancreatic cancer. Oncotarget 2018;9:3131-42. [PMID: 29423035 DOI: 10.18632/oncotarget.23220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
379 Chen J, Smaardijk S, Vandecaetsbeek I, Vangheluwe P. Regulation of Ca2+ Transport ATPases by Amino- and Carboxy-Terminal Extensions: Mechanisms and (Patho)Physiological Implications. In: Chakraborti S, Dhalla NS, editors. Regulation of Ca2+-ATPases,V-ATPases and F-ATPases. Cham: Springer International Publishing; 2016. pp. 243-79. [DOI: 10.1007/978-3-319-24780-9_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
380 Rückert F, Dawelbait G, Winter C, Hartmann A, Denz A, Ammerpohl O, Schroeder M, Schackert HK, Sipos B, Klöppel G, Kalthoff H, Saeger HD, Pilarsky C, Grützmann R. Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis. PLoS One 2010;5:e12243. [PMID: 20808857 DOI: 10.1371/journal.pone.0012243] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
381 Rajurkar M, De Jesus-Monge WE, Driscoll DR, Appleman VA, Huang H, Cotton JL, Klimstra DS, Zhu LJ, Simin K, Xu L, McMahon AP, Lewis BC, Mao J. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci U S A 2012;109:E1038-47. [PMID: 22493246 DOI: 10.1073/pnas.1114168109] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 8.1] [Reference Citation Analysis]
382 Morris JP 4th, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010;10:683-695. [PMID: 20814421 DOI: 10.1038/nrc2899] [Cited by in Crossref: 381] [Cited by in F6Publishing: 364] [Article Influence: 31.8] [Reference Citation Analysis]
383 Chang R, Chen X, Yu H, Tan G, Wen H, Huang J, Hao Z. Modified EDTA selectively recognized Cu2+ and its application in the disaggregation of β-amyloid-Cu (II)/Zn (II) aggregates. Journal of Inorganic Biochemistry 2020;203:110929. [DOI: 10.1016/j.jinorgbio.2019.110929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
384 Wu AA, Jaffee E, Lee V. Current Status of Immunotherapies for Treating Pancreatic Cancer. Curr Oncol Rep 2019;21:60. [PMID: 31101991 DOI: 10.1007/s11912-019-0811-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
385 Norris AL, Kamiyama H, Makohon-Moore A, Pallavajjala A, Morsberger LA, Lee K, Batista D, Iacobuzio-Donahue CA, Lin MT, Klein AP, Hruban RH, Wheelan SJ, Eshleman JR. Transflip mutations produce deletions in pancreatic cancer. Genes Chromosomes Cancer 2015;54:472-81. [PMID: 26031834 DOI: 10.1002/gcc.22258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
386 Xie L, Evangelidis T, Xie L, Bourne PE. Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput Biol 2011;7:e1002037. [PMID: 21552547 DOI: 10.1371/journal.pcbi.1002037] [Cited by in Crossref: 127] [Cited by in F6Publishing: 109] [Article Influence: 11.5] [Reference Citation Analysis]
387 Chalabi-dchar M, Cassant-sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle M, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, Bousquet C. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. Gastroenterology 2015;148:1452-65. [DOI: 10.1053/j.gastro.2015.02.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
388 Makawita S, Smith C, Batruch I, Zheng Y, Rückert F, Grützmann R, Pilarsky C, Gallinger S, Diamandis EP. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics 2011;10:M111.008599. [PMID: 21653254 DOI: 10.1074/mcp.M111.008599] [Cited by in Crossref: 78] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
389 Li L, Li Z, Kong X, Xie D, Jia Z, Jiang W, Cui J, Du Y, Wei D, Huang S. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells. Gastroenterology. 2014;147:485-497.e18. [PMID: 24859161 DOI: 10.1053/j.gastro.2014.04.048] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
390 Hruban RH, Klimstra DS. Adenocarcinoma of the pancreas. Semin Diagn Pathol 2014;31:443-51. [PMID: 25441308 DOI: 10.1053/j.semdp.2014.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
391 Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148:362-375. [PMID: 22265421 DOI: 10.1016/j.cell.2011.11.060.computational] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
392 Pitarresi JR, Liu X, Avendano A, Thies KA, Sizemore GM, Hammer AM, Hildreth BE 3rd, Wang DJ, Steck SA, Donohue S, Cuitiño MC, Kladney RD, Mace TA, Chang JJ, Ennis CS, Li H, Reeves RH, Blackshaw S, Zhang J, Yu L, Fernandez SA, Frankel WL, Bloomston M, Rosol TJ, Lesinski GB, Konieczny SF, Guttridge DC, Rustgi AK, Leone G, Song JW, Wu J, Ostrowski MC. Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth. Life Sci Alliance 2018;1:e201800190. [PMID: 30456390 DOI: 10.26508/lsa.201800190] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
393 He Y, Blackford JA Jr, Kohn EC, Simons SS Jr. STAMP alters the growth of transformed and ovarian cancer cells. BMC Cancer 2010;10:128. [PMID: 20374646 DOI: 10.1186/1471-2407-10-128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
394 George B. Precision Medicine and Pancreatic Cancer. Surg Oncol Clin N Am 2021;30:693-708. [PMID: 34511190 DOI: 10.1016/j.soc.2021.06.008] [Reference Citation Analysis]
395 Wan C, Chang W, Zhang Y, Shah F, Lu X, Zang Y, Zhang A, Cao S, Fishel ML, Ma Q, Zhang C. LTMG: a novel statistical modeling of transcriptional expression states in single-cell RNA-Seq data. Nucleic Acids Res 2019;47:e111. [PMID: 31372654 DOI: 10.1093/nar/gkz655] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
396 Bazzichetto C, Conciatori F, Luchini C, Simionato F, Santoro R, Vaccaro V, Corbo V, Falcone I, Ferretti G, Cognetti F, Melisi D, Scarpa A, Ciuffreda L, Milella M. From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. Cells 2020;9:E309. [PMID: 32012917 DOI: 10.3390/cells9020309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
397 Froeling FEM, Casolino R, Pea A, Biankin AV, Chang DK. Molecular Subtyping and Precision Medicine for Pancreatic Cancer. J Clin Med 2021;10:E149. [PMID: 33406790 DOI: 10.3390/jcm10010149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
398 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
399 Bednar F, Simeone DM. Pancreatic cancer stem cell biology and its therapeutic implications. J Gastroenterol. 2011;46:1345-1352. [PMID: 22048257 DOI: 10.1007/s00535-011-0494-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
400 Gadaleta E, Cutts RJ, Kelly GP, Crnogorac-Jurcevic T, Kocher HM, Lemoine NR, Chelala C. A global insight into a cancer transcriptional space using pancreatic data: importance, findings and flaws. Nucleic Acids Res 2011;39:7900-7. [PMID: 21724610 DOI: 10.1093/nar/gkr533] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
401 Shan M, Su Y, Kang W, Gao R, Li X, Zhang G. Aberrant expression and functions of protocadherins in human malignant tumors. Tumour Biol 2016;37:12969-81. [PMID: 27449047 DOI: 10.1007/s13277-016-5169-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
402 Dreyer SB, Jamieson NB, Upstill-Goddard R, Bailey PJ, McKay CJ, Biankin AV, Chang DK; Australian Pancreatic Cancer Genome Initiative. Defining the molecular pathology of pancreatic body and tail adenocarcinoma. Br J Surg 2018;105:e183-91. [PMID: 29341146 DOI: 10.1002/bjs.10772] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
403 Tan H, Bao J, Zhou X. Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity. Sci Rep 2015;5:12566. [PMID: 26212640 DOI: 10.1038/srep12566] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 8.9] [Reference Citation Analysis]
404 Nelson SR, Walsh N. Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients. Cancers (Basel) 2020;12:E1233. [PMID: 32423157 DOI: 10.3390/cancers12051233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
405 Lee YS, Cho YS, Lee GK, Lee S, Kim YW, Jho S, Kim HM, Hong SH, Hwang JA, Kim SY. Genomic profile analysis of diffuse-type gastric cancers. Genome Biol. 2014;15:R55. [PMID: 24690483 DOI: 10.1186/gb-2014-15-4-r55] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
406 Regel I, Hausmann S, Benitz S, Esposito I, Kleeff J. Pathobiology of pancreatic cancer: implications on therapy. Expert Rev Anticancer Ther 2016;16:219-27. [PMID: 26652651 DOI: 10.1586/14737140.2016.1129276] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
407 Christ A, Herzog K, Willnow TE. LRP2, an auxiliary receptor that controls sonic hedgehog signaling in development and disease. Dev Dyn 2016;245:569-79. [PMID: 26872844 DOI: 10.1002/dvdy.24394] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
408 Gonzalo DH, Lai KK, Shadrach B, Goldblum JR, Bennett AE, Downs-Kelly E, Liu X, Henricks W, Patil DT, Carver P, Na J, Gopalan B, Rybicki L, Pai RK. Gene expression profiling of serrated polyps identifies annexin A10 as a marker of a sessile serrated adenoma/polyp. J Pathol. 2013;230:420-429. [PMID: 23595865 DOI: 10.1002/path.4200] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 5.8] [Reference Citation Analysis]
409 Parkin A, Man J, Chou A, Nagrial AM, Samra J, Gill AJ, Timpson P, Pajic M. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases 2018;6:E103. [PMID: 30428574 DOI: 10.3390/diseases6040103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
410 Camici M, Garcia-Gil M, Pesi R, Allegrini S, Tozzi MG. Purine-Metabolising Enzymes and Apoptosis in Cancer. Cancers (Basel) 2019;11:E1354. [PMID: 31547393 DOI: 10.3390/cancers11091354] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
411 Fox EJ, Salk JJ, Loeb LA. Cancer genome sequencing--an interim analysis. Cancer Res 2009;69:4948-50. [PMID: 19509220 DOI: 10.1158/0008-5472.CAN-09-1231] [Cited by in Crossref: 53] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
412 Zhao Y, Sun Y. Cullin-RING Ligases as attractive anti-cancer targets. Curr Pharm Des 2013;19:3215-25. [PMID: 23151137 DOI: 10.2174/13816128113199990300] [Cited by in Crossref: 149] [Cited by in F6Publishing: 148] [Article Influence: 16.6] [Reference Citation Analysis]
413 O'Reilly EM. Adjuvant therapy for pancreas adenocarcinoma. J Surg Oncol 2013;107:78-85. [PMID: 22886586 DOI: 10.1002/jso.23230] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
414 Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E, Walde D, Goel R, Southwood B, Gauthier I, Walsh W, McIntosh L, Seymour L. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Invest New Drugs 2012;30:779-86. [PMID: 21170669 DOI: 10.1007/s10637-010-9611-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
415 Zhou B, Irwanto A, Guo Y, Bei J, Wu Q, Chen G, Zhang T, Lei J, Feng Q, Chen L, Liu J, Zhao Y. Exome sequencing and digital PCR analyses reveal novel mutated genes related to the metastasis of pancreatic ductal adenocarcinoma. Cancer Biology & Therapy 2014;13:871-9. [DOI: 10.4161/cbt.20839] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
416 Yang J, Li Y, Sun Z, Zhan H. Macrophages in pancreatic cancer: An immunometabolic perspective. Cancer Lett 2021;498:188-200. [PMID: 33122097 DOI: 10.1016/j.canlet.2020.10.029] [Reference Citation Analysis]
417 Baraniskin A, Nöpel-Dünnebacke S, Ahrens M, Jensen SG, Zöllner H, Maghnouj A, Wos A, Mayerle J, Munding J, Kost D. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer. 2013;132:E48-E57. [PMID: 22907602 DOI: 10.1002/ijc.27791] [Cited by in Crossref: 98] [Cited by in F6Publishing: 91] [Article Influence: 9.8] [Reference Citation Analysis]
418 Kitzing TM, Wang Y, Pertz O, Copeland JW, Grosse R. Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC. Oncogene. 2010;29:2441-2448. [PMID: 20101212 DOI: 10.1038/onc.2009.515] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 8.2] [Reference Citation Analysis]
419 Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80-104. [PMID: 26299994 DOI: 10.1016/j.pharmthera.2015.08.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
420 Barrett MT, Deiotte R, Lenkiewicz E, Malasi S, Holley T, Evers L, Posner RG, Jones T, Han H, Sausen M, Velculescu VE, Drebin J, O'Dwyer P, Jameson G, Ramanathan RK, Von Hoff DD. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Br J Cancer 2017;117:572-82. [PMID: 28720843 DOI: 10.1038/bjc.2017.209] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
421 Geraci G, D'Elia I, del Gaudio R, Di Giaimo R. Evidence of genetic instability in tumors and normal nearby tissues. PLoS One 2010;5:e9343. [PMID: 20186333 DOI: 10.1371/journal.pone.0009343] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
422 Yamada S, Fujii T, Shimoyama Y, Kanda M, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Nakao A, Kodera Y. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer. Pancreas 2015;44:660-4. [PMID: 25760429 DOI: 10.1097/MPA.0000000000000315] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
423 Ungefroren H, Witte D, Lehnert H. The role of small GTPases of the Rho/Rac family in TGF-β-induced EMT and cell motility in cancer: ROLE OF SMALL GTPASES IN CANCER. Dev Dyn 2018;247:451-61. [DOI: 10.1002/dvdy.24505] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
424 Rao CV, Janakiram NB, Mohammed A. Molecular Pathways: Mucins and Drug Delivery in Cancer. Clin Cancer Res 2017;23:1373-8. [PMID: 28039261 DOI: 10.1158/1078-0432.CCR-16-0862] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
425 Kandel P, Nassar A, Gomez V, Raimondo M, Woodward TA, Crook JE, Fares NS, Wallace MB. Comparison of endoscopic ultrasound-guided fine-needle biopsy versus fine-needle aspiration for genomic profiling and DNA yield in pancreatic cancer: a randomized crossover trial. Endoscopy. 2021;53:376-382. [PMID: 32767288 DOI: 10.1055/a-1223-2171] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
426 Cardin DB, Goff LW, Chan E, Whisenant JG, Dan Ayers G, Takebe N, Arlinghaus LR, Yankeelov TE, Berlin J, Merchant N. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 2018;36:442-50. [PMID: 28990119 DOI: 10.1007/s10637-017-0519-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
427 Garcia PE, Scales MK, Allen BL, Pasca di Magliano M. Pancreatic Fibroblast Heterogeneity: From Development to Cancer. Cells 2020;9:E2464. [PMID: 33198201 DOI: 10.3390/cells9112464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
428 Giulietti M, Occhipinti G, Principato G, Piva F. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis. Cell Oncol (Dordr) 2017;40:181-92. [PMID: 28205147 DOI: 10.1007/s13402-017-0315-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 9.6] [Reference Citation Analysis]
429 Napoli C, Sperandio N, Lawlor RT, Scarpa A, Molinari H, Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. J Proteome Res. 2012;11:1274-1283. [PMID: 22066465 DOI: 10.1021/pr200960u] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
430 Gilson P. Enrichment and Analysis of ctDNA. Recent Results Cancer Res. 2020;215:181-211. [PMID: 31605230 DOI: 10.1007/978-3-030-26439-0_10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
431 Bai Y, Qiao L, Xie N, Li Y, Nie Y, Pan Y, Shi Y, Wang J, Liu N. TOB1 suppresses proliferation in K-Ras wild-type pancreatic cancer. Cancer Med 2020;9:1503-14. [PMID: 31891232 DOI: 10.1002/cam4.2756] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
432 Principe DR, DeCant B, Mascariñas E, Wayne EA, Diaz AM, Akagi N, Hwang R, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, Grippo PJ. TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. Cancer Res 2016;76:2525-39. [PMID: 26980767 DOI: 10.1158/0008-5472.CAN-15-1293] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 14.3] [Reference Citation Analysis]
433 Chen X, Chen J, Shao B, Zhao L, Yue H, Ouyang Q. Relationship between cancer mutations and parameter sensitivity in Rb pathway. J Theor Biol 2016;404:120-5. [PMID: 27181371 DOI: 10.1016/j.jtbi.2016.05.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
434 Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 2012;33:100-103. [PMID: 22009941 DOI: 10.1002/humu.21633] [Cited by in Crossref: 190] [Cited by in F6Publishing: 178] [Article Influence: 17.3] [Reference Citation Analysis]
435 Tan DJ, Mitra M, Chiu AM, Coller HA. Intron retention is a robust marker of intertumoral heterogeneity in pancreatic ductal adenocarcinoma. NPJ Genom Med 2020;5:55. [PMID: 33311498 DOI: 10.1038/s41525-020-00159-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
436 Brosens RP, Haan JC, Carvalho B, Rustenburg F, Grabsch H, Quirke P, Engel AF, Cuesta MA, Maughan N, Flens M, Meijer GA, Ylstra B. Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. J Pathol 2010;221:411-24. [PMID: 20593488 DOI: 10.1002/path.2724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 22] [Article Influence: 0.2] [Reference Citation Analysis]
437 Seshacharyulu P, Baine MJ, Souchek JJ, Menning M, Kaur S, Yan Y, Ouellette MM, Jain M, Lin C, Batra SK. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2017;1868:69-92. [PMID: 28249796 DOI: 10.1016/j.bbcan.2017.02.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
438 D'Antonio M, Pendino V, Sinha S, Ciccarelli FD. Network of Cancer Genes (NCG 3.0): integration and analysis of genetic and network properties of cancer genes. Nucleic Acids Res 2012;40:D978-83. [PMID: 22080562 DOI: 10.1093/nar/gkr952] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
439 Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, Cresta S, Gargiulo E, Forconi F, Guarini A, Arcaini L, Paulli M, Laurenti L, Larocca LM, Marasca R, Gattei V, Oscier D, Bertoni F, Mullighan CG, Foá R, Pasqualucci L, Rabadan R, Dalla-Favera R, Gaidano G. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389-401. [PMID: 21670202 DOI: 10.1084/jem.20110921] [Cited by in Crossref: 428] [Cited by in F6Publishing: 396] [Article Influence: 38.9] [Reference Citation Analysis]
440 Guo Y, Dong X, Jin J, He Y. The Expression Patterns and Prognostic Value of the Proteasome Activator Subunit Gene Family in Gastric Cancer Based on Integrated Analysis. Front Cell Dev Biol 2021;9:663001. [PMID: 34650966 DOI: 10.3389/fcell.2021.663001] [Reference Citation Analysis]
441 Sun C, Rosendahl AH, Andersson R, Wu D, Wang X. The role of phosphatidylinositol 3-kinase signaling pathways in pancreatic cancer. Pancreatology 2011;11:252-60. [PMID: 21625196 DOI: 10.1159/000327715] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
442 Pergolini I, Morales-Oyarvide V, Mino-Kenudson M, Honselmann KC, Rosenbaum MW, Nahar S, Kem M, Ferrone CR, Lillemoe KD, Bardeesy N, Ryan DP, Thayer SP, Warshaw AL, Fernández-Del Castillo C, Liss AS. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One 2017;12:e0182855. [PMID: 28854237 DOI: 10.1371/journal.pone.0182855] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
443 Showalter SL, Charles S, Belin J, Cozzitorto J, Einstein P, Richards NG, Sauter PK, Kennedy EP, Witkiewicz A, Brody JR, Yeo CJ. Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. Expert Opinion on Drug Delivery 2010;7:273-84. [DOI: 10.1517/17425240903544462] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
444 Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O’Dwyer P, Haller D, Catalano P. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778-3785. [PMID: 19581537 DOI: 10.1200/jco.2008.20.9007] [Cited by in Crossref: 285] [Cited by in F6Publishing: 150] [Article Influence: 21.9] [Reference Citation Analysis]
445 Brognard J, Hunter T. Protein kinase signaling networks in cancer. Curr Opin Genet Dev 2011;21:4-11. [PMID: 21123047 DOI: 10.1016/j.gde.2010.10.012] [Cited by in Crossref: 157] [Cited by in F6Publishing: 129] [Article Influence: 13.1] [Reference Citation Analysis]
446 Mcdermott U, Settleman J. Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology. JCO 2009;27:5650-9. [DOI: 10.1200/jco.2009.22.9054] [Cited by in Crossref: 93] [Cited by in F6Publishing: 49] [Article Influence: 7.2] [Reference Citation Analysis]
447 Thomas RM, Jaquish DV, French RP, Lowy AM. The RON Tyrosine Kinase Receptor Regulates Vascular Endothelial Growth Factor Production in Pancreatic Cancer Cells. Pancreas 2010;39:301-7. [DOI: 10.1097/mpa.0b013e3181bb9f73] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
448 O'Reilly EM. Adjuvant therapy for pancreas adenocarcinoma: where are we going? Expert Rev Anticancer Ther 2011;11:173-7. [PMID: 21342036 DOI: 10.1586/era.10.232] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
449 Caravagna G, Graudenzi A, Ramazzotti D, Sanz-Pamplona R, De Sano L, Mauri G, Moreno V, Antoniotti M, Mishra B. Algorithmic methods to infer the evolutionary trajectories in cancer progression. Proc Natl Acad Sci U S A 2016;113:E4025-34. [PMID: 27357673 DOI: 10.1073/pnas.1520213113] [Cited by in Crossref: 50] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
450 Mendieta Zerón H, García Flores JR, Romero Prieto ML. Limitations in improving detection of pancreatic adenocarcinoma. Future Oncol. 2009;5:657-668. [PMID: 19519205 DOI: 10.2217/fon.09.32] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
451 Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS; Cancer and Leukemia Group B. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. Cancer 2011;117:2620-8. [PMID: 21656739 DOI: 10.1002/cncr.25742] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
452 Kuboki Y, Fischer CG, Beleva Guthrie V, Huang W, Yu J, Chianchiano P, Hosoda W, Zhang H, Zheng L, Shao X, Thompson ED, Waters K, Poling J, He J, Weiss MJ, Wolfgang CL, Goggins MG, Hruban RH, Roberts NJ, Karchin R, Wood LD. Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. J Pathol 2019;247:347-56. [PMID: 30430578 DOI: 10.1002/path.5194] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
453 Basu A, Alder H, Khiyami A, Leahy P, Croce CM, Haldar S. MicroRNA-375 and MicroRNA-221: Potential Noncoding RNAs Associated with Antiproliferative Activity of Benzyl Isothiocyanate in Pancreatic Cancer. Genes Cancer. 2011;2:108-119. [PMID: 21779484 DOI: 10.1177/1947601911409212] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
454 Brody JP. Parallel routes of human carcinoma development: implications of the age-specific incidence data. PLoS One 2009;4:e7053. [PMID: 19774079 DOI: 10.1371/journal.pone.0007053] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
455 Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016;45:370-375. [PMID: 26390428 DOI: 10.1097/mpa.0000000000000458] [Cited by in Crossref: 103] [Cited by in F6Publishing: 71] [Article Influence: 17.2] [Reference Citation Analysis]
456 Kendrick ZW, Firpo MA, Repko RC, Scaife CL, Adler DG, Boucher KM, Mulvihill SJ. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. HPB (Oxford). 2014;16:670-676. [PMID: 24308545 DOI: 10.1111/hpb.12199] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
457 Guseva LN. [Nitritometric determination of allacyl]. Farmatsiia. 1969;18:43-45. [PMID: 5793409 DOI: 10.1186/s13045-017-0551-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
458 Rozengurt E, Eibl G. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. World J Gastroenterol 2019; 25(15): 1797-1816 [PMID: 31057295 DOI: 10.3748/wjg.v25.i15.1797] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
459 Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med 2017;15:133. [PMID: 28716075 DOI: 10.1186/s12916-017-0900-y] [Cited by in Crossref: 89] [Cited by in F6Publishing: 89] [Article Influence: 17.8] [Reference Citation Analysis]
460 Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan Ş, Eng S, Kannan K, Zou Y, Peng L, Banuchi VE, Paty P, Zeng Z, Vakiani E, Solit D, Singh B, Ganly I, Liau L, Cloughesy TC, Mischel PS, Mellinghoff IK, Chan TA. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet 2013;45:253-61. [PMID: 23354438 DOI: 10.1038/ng.2538] [Cited by in Crossref: 203] [Cited by in F6Publishing: 184] [Article Influence: 22.6] [Reference Citation Analysis]
461 Wood LD, Hruban RH. Genomic landscapes of pancreatic neoplasia. J Pathol Transl Med 2015;49:13-22. [PMID: 25812653 DOI: 10.4132/jptm.2014.12.26] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
462 Loft M, Lee B, Tie J, Gibbs P. Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. J Pers Med 2019;9:E37. [PMID: 31323810 DOI: 10.3390/jpm9030037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
463 Loh SN. The missing zinc: p53 misfolding and cancer. Metallomics 2010;2:442-9. [PMID: 21072344 DOI: 10.1039/c003915b] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
464 Akhtar A, Xiaoyan Wang S, Ghali L, Bell C, Wen X. Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers. J Biomed Res 2017;31:177-88. [PMID: 28808212 DOI: 10.7555/JBR.31.20160059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
465 Liu P, Ren J, Xiong Y, Yang Z, Zhu W, He Q, Xu Z, He W, Wang J. Enhancing magnetic resonance/photoluminescence imaging-guided photodynamic therapy by multiple pathways. Biomaterials 2019;199:52-62. [PMID: 30738335 DOI: 10.1016/j.biomaterials.2019.01.044] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
466 Nelson BH, Webb JR. Tumor-Specific Mutations as Targets for Cancer Immunotherapy. In: Medin J, Fowler D, editors. Experimental and Applied Immunotherapy. Totowa: Humana Press; 2011. pp. 151-72. [DOI: 10.1007/978-1-60761-980-2_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
467 Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 2010;11:1039-43. [DOI: 10.2217/pgs.10.104] [Cited by in Crossref: 71] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
468 Fang C, Guo X, Lv X, Yin R, Lv X, Wang F, Zhao J, Bai Q, Yao X, Chen Y. Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K. J Mol Cell Biol 2017;9:504-15. [PMID: 29040676 DOI: 10.1093/jmcb/mjx043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
469 Huang W, Navarro-Serer B, Jeong YJ, Chianchiano P, Xia L, Luchini C, Veronese N, Dowiak C, Ng T, Trujillo MA, Huang B, Pflüger MJ, Macgregor-Das AM, Lionheart G, Jones D, Fujikura K, Nguyen-Ngoc KV, Neumann NM, Groot VP, Hasanain A, van Oosten AF, Fischer SE, Gallinger S, Singhi AD, Zureikat AH, Brand RE, Gaida MM, Heinrich S, Burkhart RA, He J, Wolfgang CL, Goggins MG, Thompson ED, Roberts NJ, Ewald AJ, Wood LD. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Cancer Res 2020;80:2804-17. [PMID: 32376602 DOI: 10.1158/0008-5472.CAN-19-1523] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
470 Diaz-Colunga J, Diaz-Uriarte R. Conditional prediction of consecutive tumor evolution using cancer progression models: What genotype comes next? PLoS Comput Biol 2021;17:e1009055. [PMID: 34932572 DOI: 10.1371/journal.pcbi.1009055] [Reference Citation Analysis]
471 Wong CH, Li YJ, Chen YC. Therapeutic potential of targeting acinar cell reprogramming in pancreatic cancer. World J Gastroenterol 2016; 22(31): 7046-7057 [PMID: 27610015 DOI: 10.3748/wjg.v22.i31.7046] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
472 Balic A, Dorado J, Alonso-Gómez M, Heeschen C. Stem cells as the root of pancreatic ductal adenocarcinoma. Exp Cell Res 2012;318:691-704. [PMID: 22119145 DOI: 10.1016/j.yexcr.2011.11.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
473 Tian WD, Ma YQ. Theoretical and computational studies of dendrimers as delivery vectors. Chem Soc Rev 2013;42:705-27. [PMID: 23114420 DOI: 10.1039/c2cs35306g] [Cited by in Crossref: 169] [Cited by in F6Publishing: 28] [Article Influence: 18.8] [Reference Citation Analysis]
474 Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology. 2016;150:48-63. [PMID: 26385075 DOI: 10.1053/j.gastro.2015.08.056] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 9.0] [Reference Citation Analysis]
475 Gonzalez-Perez A, Jene-Sanz A, Lopez-Bigas N. The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. Genome Biol 2013;14:r106. [PMID: 24063517 DOI: 10.1186/gb-2013-14-9-r106] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 10.4] [Reference Citation Analysis]
476 Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, Wang K, Ross JS, Sharma S. N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience 2015;2:285-93. [PMID: 25897431 DOI: 10.18632/oncoscience.141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
477 di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology. 2013;144:1220-1229. [PMID: 23622131 DOI: 10.1053/j.gastro.2013.01.071] [Cited by in Crossref: 230] [Cited by in F6Publishing: 218] [Article Influence: 25.6] [Reference Citation Analysis]
478 Takeuchi S, Doi M, Ikari N, Yamamoto M, Furukawa T. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma. Sci Rep 2018;8:8105. [PMID: 29802286 DOI: 10.1038/s41598-018-26526-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
479 Hata T, Dal Molin M, McGregor-Das A, Song TJ, Wolfgang C, Eshleman JR, Hruban RH, Goggins M. Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. J Mol Diagn 2018;20:46-55. [PMID: 29229290 DOI: 10.1016/j.jmoldx.2017.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
480 Chen SH, Dallas MR, Balzer EM, Konstantopoulos K. Mucin 16 is a functional selectin ligand on pancreatic cancer cells. FASEB J. 2012;26:1349-1359. [PMID: 22159147 DOI: 10.1096/fj.11-195669] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
481 Arpin CC, Mac S, Jiang Y, Cheng H, Grimard M, Page BD, Kamocka MM, Haftchenary S, Su H, Ball DP, Rosa DA, Lai PS, Gómez-Biagi RF, Ali AM, Rana R, Hanenberg H, Kerman K, McElyea KC, Sandusky GE, Gunning PT, Fishel ML. Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics. Mol Cancer Ther 2016;15:794-805. [PMID: 26873728 DOI: 10.1158/1535-7163.MCT-15-0003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
482 Löffler H, Pfarr N, Kriegsmann M, Endris V, Hielscher T, Lohneis P, Folprecht G, Stenzinger A, Dietel M, Weichert W, Krämer A. Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget 2016;7:44322-9. [PMID: 27322425 DOI: 10.18632/oncotarget.10035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
483 Kreiter S, Diken M, Sahin U. mRNA Vaccination and Personalized Cancer Therapy. In: Britten CM, Kreiter S, Diken M, Rammensee H, editors. Cancer Immunotherapy Meets Oncology. Cham: Springer International Publishing; 2014. pp. 89-100. [DOI: 10.1007/978-3-319-05104-8_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
484 Dal Molin M, Hong SM, Hebbar S, Sharma R, Scrimieri F, de Wilde RF, Mayo SC, Goggins M, Wolfgang CL, Schulick RD. Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. Hum Pathol. 2012;43:585-591. [PMID: 21940037 DOI: 10.1016/j.humpath.2011.06.009] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
485 Brouwer TP, Vahrmeijer AL, de Miranda NFCC. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cell Oncol (Dordr) 2021;44:261-78. [PMID: 33710604 DOI: 10.1007/s13402-021-00587-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
486 Cho WC. [Targeting the signaling pathways in cancer therapy]. Zhongguo Fei Ai Za Zhi 2012;15:C13-5. [PMID: 23677000 DOI: 10.3779/j.issn.1009-3419.2012.09.10] [Reference Citation Analysis]
487 Polireddy K, Dong R, Reed G, Yu J, Chen P, Williamson S, Violet PC, Pessetto Z, Godwin AK, Fan F, Levine M, Drisko JA, Chen Q. High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study. Sci Rep 2017;7:17188. [PMID: 29215048 DOI: 10.1038/s41598-017-17568-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
488 Veite-Schmahl MJ, Rivers AC, Regan DP, Kennedy MA. The Mouse Model of Pancreatic Cancer Atlas (MMPCA) for classification of pancreatic cancer lesions: A large histological investigation of the Ptf1aCre/+;LSL-KrasG12D/+ transgenic mouse model of pancreatic cancer. PLoS One 2017;12:e0187552. [PMID: 29121082 DOI: 10.1371/journal.pone.0187552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
489 Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomarkers in Medicine 2010;4:583-6. [DOI: 10.2217/bmm.10.70] [Cited by in Crossref: 81] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
490 Emerson AI, Andrews S, Ahmed I, Azis TK, Malek JA. K-core decomposition of a protein domain co-occurrence network reveals lower cancer mutation rates for interior cores. J Clin Bioinforma 2015;5:1. [PMID: 25767694 DOI: 10.1186/s13336-015-0016-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
491 Monsurrò V, Beghelli S, Wang R, Barbi S, Coin S, Di Pasquale G, Bersani S, Castellucci M, Sorio C, Eleuteri S, Worschech A, Chiorini JA, Pederzoli P, Alter H, Marincola FM, Scarpa A. Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J Transl Med 2010;8:10. [PMID: 20113473 DOI: 10.1186/1479-5876-8-10] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
492 Swanton C, Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer 2009;100:1517-22. [PMID: 19367275 DOI: 10.1038/sj.bjc.6605031] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
493 Lomberk G, Dusetti N, Iovanna J, Urrutia R. Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine. Nat Commun 2019;10:3875. [PMID: 31462645 DOI: 10.1038/s41467-019-11812-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
494 Baer R, Cintas C, Therville N, Guillermet-Guibert J. Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter? Adv Biol Regul. 2015;59:19-35. [PMID: 26166735 DOI: 10.1016/j.jbior.2015.05.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
495 Roukos DH, Tzakos A, Zografos G. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 2009;9:1413-6. [PMID: 19828000 DOI: 10.1586/era.09.116] [Cited by in Crossref: 71] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
496 Houg DS, Bijlsma MF. The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma. Mol Cancer. 2018;17:95. [PMID: 29903049 DOI: 10.1186/s12943-018-0842-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
497 Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors’ down-regulation and dimers’ disruption. Neoplasia. 2012;14:121-130. [PMID: 22431920 DOI: 10.1593/neo.111602] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.3] [Reference Citation Analysis]
498 Labat-de-Hoz L, Alonso MA. Formins in Human Disease. Cells 2021;10:2554. [PMID: 34685534 DOI: 10.3390/cells10102554] [Reference Citation Analysis]
499 Kohutek ZA, Rosati LM, Hong J, Poling J, Attiyeh MA, Makohon-Moore A, Herman JM, Iacobuzio-Donahue CA. An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course. Cold Spring Harb Mol Case Stud 2017;3:a001701. [PMID: 28679692 DOI: 10.1101/mcs.a001701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
500 Frampton AE, Krell J, Giovannetti E, Krell D, Stebbing J, Castellano L, Jiao LR. Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. Expert Rev Anticancer Ther 2012;12:1275-8. [PMID: 23176615 DOI: 10.1586/era.12.108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
501 Zhou YY, Chen LP, Zhang Y, Hu SK, Dong ZJ, Wu M, Chen QX, Zhuang ZZ, Du XJ. Integrated transcriptomic analysis reveals hub genes involved in diagnosis and prognosis of pancreatic cancer. Mol Med 2019;25:47. [PMID: 31706267 DOI: 10.1186/s10020-019-0113-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
502 Mathur R, Sharma L, Dhabhai B, Menon AM, Sharma A, Sharma NK, Dakal TC. Predicting the functional consequences of genetic variants in co-stimulatory ligand B7-1 using in-silico approaches. Hum Immunol 2021;82:103-20. [PMID: 33358455 DOI: 10.1016/j.humimm.2020.12.001] [Reference Citation Analysis]
503 Ding C, Li Y, Xing C, Zhang H, Wang S, Dai M. Research Progress on Slit/Robo Pathway in Pancreatic Cancer: Emerging and Promising. J Oncol 2020;2020:2845906. [PMID: 32670371 DOI: 10.1155/2020/2845906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
504 Silke J, O'Reilly LA. NF-κB and Pancreatic Cancer; Chapter and Verse. Cancers (Basel) 2021;13:4510. [PMID: 34572737 DOI: 10.3390/cancers13184510] [Reference Citation Analysis]
505 López-Otín C, Palavalli LH, Samuels Y. Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle 2009;8:3657-62. [PMID: 19844170 DOI: 10.4161/cc.8.22.9956] [Cited by in Crossref: 92] [Cited by in F6Publishing: 80] [Article Influence: 7.1] [Reference Citation Analysis]
506 Yang XY, Guan M, Vigil D, Der CJ, Lowy DR, Popescu NC. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene 2009;28:1401-9. [PMID: 19151751 DOI: 10.1038/onc.2008.498] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
507 Moran GR, Hoag MR. The enzyme: Renalase. Arch Biochem Biophys 2017;632:66-76. [PMID: 28558965 DOI: 10.1016/j.abb.2017.05.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
508 Mammano E, Galdi F, Pierobon M, Tessari E, Deng J, Pucciarelli S, Agostini M, De Marchi F, Canzonieri V, De Paoli A. Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment. Clin Colorectal Cancer. 2012;11:268-274. [PMID: 22658458 DOI: 10.1016/j.clcc.2012.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
509 Tian C, Li X, Ge C. High expression of LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: a comprehensive TCGA analysis. Mol Med 2021;27:62. [PMID: 34134622 DOI: 10.1186/s10020-021-00322-2] [Reference Citation Analysis]
510 Taylor JG 6th, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J, Kim SY, Yeung C, Helman LJ, Mendoza A, Ngo V, Staudt LM, Wei JS, Khanna C, Catchpoole D, Qualman SJ, Hewitt SM, Merlino G, Chanock SJ, Khan J. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009;119:3395-407. [PMID: 19809159 DOI: 10.1172/JCI39703] [Cited by in Crossref: 22] [Cited by in F6Publishing: 124] [Article Influence: 1.7] [Reference Citation Analysis]
511 Eddy JA, Hood L, Price ND, Geman D. Identifying tightly regulated and variably expressed networks by Differential Rank Conservation (DIRAC). PLoS Comput Biol 2010;6:e1000792. [PMID: 20523739 DOI: 10.1371/journal.pcbi.1000792] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
512 Timmermann B, Kerick M, Roehr C, Fischer A, Isau M, Boerno ST, Wunderlich A, Barmeyer C, Seemann P, Koenig J. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One. 2010;5:e15661. [PMID: 21203531 DOI: 10.1371/journal.pone.0015661] [Cited by in Crossref: 150] [Cited by in F6Publishing: 137] [Article Influence: 12.5] [Reference Citation Analysis]
513 Beuran M, Negoi I, Paun S, Ion AD, Bleotu C, Negoi RI, Hostiuc S. The epithelial to mesenchymal transition in pancreatic cancer: A systematic review. Pancreatology. 2015;15:217-225. [PMID: 25794655 DOI: 10.1016/j.pan.2015.02.011] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 10.7] [Reference Citation Analysis]
514 Ocak S, Sos ML, Thomas RK, Massion PP. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Eur Respir J 2009;34:489-506. [PMID: 19648524 DOI: 10.1183/09031936.00042409] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
515 Mizuma M, Rasheed ZA, Yabuuchi S, Omura N, Campbell NR, de Wilde RF, De Oliveira E, Zhang Q, Puig O, Matsui W. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol Cancer Ther. 2012;11:1999-2009. [PMID: 22752426 DOI: 10.1158/1535-7163.mct-12-0017] [Cited by in Crossref: 58] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
516 Oliveira C, Calmeiro J, Carrascal MA, Falcão A, Gomes C, Miguel Neves B, Teresa Cruz M. Exosomes as new therapeutic vectors for pancreatic cancer treatment. Eur J Pharm Biopharm 2021;161:4-14. [PMID: 33561524 DOI: 10.1016/j.ejpb.2021.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
517 Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 2009;8:3112-9. [PMID: 19755856 DOI: 10.4161/cc.8.19.9626] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 6.3] [Reference Citation Analysis]
518 Radtke I, Mullighan CG, Ishii M, Su X, Cheng J, Ma J, Ganti R, Cai Z, Goorha S, Pounds SB, Cao X, Obert C, Armstrong J, Zhang J, Song G, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff SA, Downing JR. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A 2009;106:12944-9. [PMID: 19651601 DOI: 10.1073/pnas.0903142106] [Cited by in Crossref: 126] [Cited by in F6Publishing: 118] [Article Influence: 9.7] [Reference Citation Analysis]
519 Malgundkar SH, Burney I, Al Moundhri M, Al Kalbani M, Lakhtakia R, Okamoto A, Tamimi Y. FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β-catenin activity in ovarian cancer. BMC Cancer 2020;20:374. [PMID: 32366234 DOI: 10.1186/s12885-020-06900-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
520 Yi S, Liu NN, Hu L, Wang H, Sahni N. Base-resolution stratification of cancer mutations using functional variomics. Nat Protoc 2017;12:2323-41. [PMID: 28981122 DOI: 10.1038/nprot.2017.086] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
521 Tamura K, Ohtsuka T, Date K, Fujimoto T, Matsunaga T, Kimura H, Watanabe Y, Miyazaki T, Ohuchida K, Takahata S, Ishigami K, Oda Y, Mizumoto K, Nakamura M, Tanaka M. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers. Pancreas 2016;45:826-35. [PMID: 26646266 DOI: 10.1097/MPA.0000000000000563] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
522 Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, Radosevic-Robin N, Penault-Llorca F, Gongora C, Colombo PE, Lazrek Y, Bras-Goncalves R, Savina A, Azria D, Bazin H, Pèlegrin A, Larbouret C. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget 2014;5:7138-48. [PMID: 25216528 DOI: 10.18632/oncotarget.2231] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
523 Tan X, Zhou L, Wang W, Wang B, Egami H, Baba H, Dai X. Genomic analysis of invasion-metastasis-related factors in pancreatic cancer cells. Exp Ther Med 2010;1:211-6. [PMID: 23136617 DOI: 10.3892/etm_00000034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
524 Patel K, Kollory A, Takashima A, Sarkar S, Faller DV, Ghosh SK. MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression. Cancer Lett. 2014;347:54-64. [PMID: 24491408 DOI: 10.1016/j.canlet.2014.01.020] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
525 Bufalieri F, Infante P, Bernardi F, Caimano M, Romania P, Moretti M, Lospinoso Severini L, Talbot J, Melaiu O, Tanori M, Di Magno L, Bellavia D, Capalbo C, Puget S, De Smaele E, Canettieri G, Guardavaccaro D, Busino L, Peschiaroli A, Pazzaglia S, Giannini G, Melino G, Locatelli F, Gulino A, Ayrault O, Fruci D, Di Marcotullio L. ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of βTrCP. Nat Commun 2019;10:3304. [PMID: 31341163 DOI: 10.1038/s41467-019-11093-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
526 Zheng CH, Yang W, Chong YW, Xia JF. Identification of mutated driver pathways in cancer using a multi-objective optimization model. Comput Biol Med 2016;72:22-9. [PMID: 26995027 DOI: 10.1016/j.compbiomed.2016.03.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
527 Miyoshi E, Kamada Y. Application of glycoscience to the early detection of pancreatic cancer. Cancer Sci 2016;107:1357-62. [PMID: 27418030 DOI: 10.1111/cas.13011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
528 Gonzalez-Perez A, Deu-Pons J, Lopez-Bigas N. Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation. Genome Med 2012;4:89. [PMID: 23181723 DOI: 10.1186/gm390] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 7.3] [Reference Citation Analysis]
529 Turner A, Bond DR, Vuong QV, Chalmers A, Beckett EL, Weidenhofer J, Scarlett CJ. Elaeocarpus reticulatus fruit extracts reduce viability and induce apoptosis in pancreatic cancer cells in vitro. Mol Biol Rep 2020;47:2073-84. [PMID: 32065323 DOI: 10.1007/s11033-020-05307-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
530 Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 2009;461:218-23. [PMID: 19741703 DOI: 10.1038/nature08454] [Cited by in Crossref: 554] [Cited by in F6Publishing: 453] [Article Influence: 42.6] [Reference Citation Analysis]
531 Collins MA, Bednar F, Zhang Y, Brisset JC, Galbán S, Galbán CJ, Rakshit S, Flannagan KS, Adsay NV, Pasca di Magliano M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012;122:639-53. [PMID: 22232209 DOI: 10.1172/JCI59227] [Cited by in Crossref: 421] [Cited by in F6Publishing: 292] [Article Influence: 42.1] [Reference Citation Analysis]
532 Qiu W, Kuo CY, Tian Y, Su GH. Dual Roles of the Activin Signaling Pathway in Pancreatic Cancer. Biomedicines 2021;9:821. [PMID: 34356885 DOI: 10.3390/biomedicines9070821] [Reference Citation Analysis]
533 Joost S, Almada LL, Rohnalter V, Holz PS, Vrabel AM, Fernandez-Barrena MG, McWilliams RR, Krause M, Fernandez-Zapico ME, Lauth M. GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. Cancer Res 2012;72:88-99. [PMID: 22086851 DOI: 10.1158/0008-5472.CAN-10-4621] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
534 Sadeque A, Serão NV, Southey BR, Delfino KR, Rodriguez-Zas SL. Identification and characterization of alternative exon usage linked glioblastoma multiforme survival. BMC Med Genomics 2012;5:59. [PMID: 23206951 DOI: 10.1186/1755-8794-5-59] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
535 Walter K, Omura N, Hong SM, Griffith M, Vincent A, Borges M, Goggins M. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin Cancer Res 2010;16:1781-9. [PMID: 20215540 DOI: 10.1158/1078-0432.CCR-09-1913] [Cited by in Crossref: 113] [Cited by in F6Publishing: 86] [Article Influence: 9.4] [Reference Citation Analysis]
536 Tran B, Dancey JE, Kamel-reid S, Mcpherson JD, Bedard PL, Brown AM, Zhang T, Shaw P, Onetto N, Stein L, Hudson TJ, Neel BG, Siu LL. Cancer Genomics: Technology, Discovery, and Translation. JCO 2012;30:647-60. [DOI: 10.1200/jco.2011.39.2316] [Cited by in Crossref: 127] [Cited by in F6Publishing: 58] [Article Influence: 12.7] [Reference Citation Analysis]
537 Crippa S, Partelli S, Zamboni G, Barugola G, Capelli P, Inama M, Bassi C, Pederzoli P, Falconi M. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile? Surgery. 2012;152:S112-S119. [PMID: 22766365 DOI: 10.1016/j.surg.2012.05.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
538 Nehrt NL, Peterson TA, Park D, Kann MG. Domain landscapes of somatic mutations in cancer. BMC Genomics 2012;13 Suppl 4:S9. [PMID: 22759657 DOI: 10.1186/1471-2164-13-S4-S9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
539 van Kampen JG, Marijnissen-van Zanten MA, Simmer F, van der Graaf WT, Ligtenberg MJ, Nagtegaal ID. Epigenetic targeting in pancreatic cancer. Cancer Treat Rev. 2014;40:656-664. [PMID: 24433955 DOI: 10.1016/j.ctrv.2013.12.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
540 Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11:220-228. [PMID: 20177397 DOI: 10.1038/nrm2858] [Cited by in Crossref: 1203] [Cited by in F6Publishing: 1111] [Article Influence: 100.3] [Reference Citation Analysis]
541 Nagrath S, Jack RM, Sahai V, Simeone DM. Opportunities and Challenges for Pancreatic Circulating Tumor Cells. Gastroenterology. 2016;151:412-426. [PMID: 27339829 DOI: 10.1053/j.gastro.2016.05.052] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
542 Longati P, Jia X, Eimer J, Wagman A, Witt MR, Rehnmark S, Verbeke C, Toftgård R, Löhr M, Heuchel RL. 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer 2013;13:95. [PMID: 23446043 DOI: 10.1186/1471-2407-13-95] [Cited by in Crossref: 214] [Cited by in F6Publishing: 198] [Article Influence: 23.8] [Reference Citation Analysis]
543 Delitto D, Wallet SM, Hughes SJ. Targeting tumor tolerance: A new hope for pancreatic cancer therapy? Pharmacol Ther. 2016;166:9-29. [PMID: 27343757 DOI: 10.1016/j.pharmthera.2016.06.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
544 Egloff AM, Grandis JR. Response to combined molecular targeting: defining the role of P-STAT3. Clin Cancer Res 2011;17:393-5. [PMID: 21266530 DOI: 10.1158/1078-0432.CCR-10-2925] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
545 Leclerc E, Vetter SW. The role of S100 proteins and their receptor RAGE in pancreatic cancer. Biochim Biophys Acta. 2015;1852:2706-2711. [PMID: 26435083 DOI: 10.1016/j.bbadis.2015.09.022] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
546 Huntosova V, Novotova M, Nichtova Z, Balogova L, Maslanakova M, Petrovajova D, Stroffekova K. Assessing light-independent effects of hypericin on cell viability, ultrastructure and metabolism in human glioma and endothelial cells. Toxicology in Vitro 2017;40:184-95. [DOI: 10.1016/j.tiv.2017.01.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
547 Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel) 2016;8:E45. [PMID: 27096871 DOI: 10.3390/cancers8040045] [Cited by in Crossref: 100] [Cited by in F6Publishing: 82] [Article Influence: 16.7] [Reference Citation Analysis]
548 Walter K, Hong SM, Nyhan S, Canto M, Fedarko N, Klein A, Griffith M, Omura N, Medghalchi S, Kuhajda F. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 2009;18:2380-2385. [PMID: 19723916 DOI: 10.1158/1055-9965.epi-09-0144] [Cited by in Crossref: 60] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
549 Lan W, Bian B, Xia Y, Dou S, Gayet O, Bigonnet M, Santofimia-Castaño P, Cong M, Peng L, Dusetti N, Iovanna J. E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments. Sci Rep 2018;8:8330. [PMID: 29844366 DOI: 10.1038/s41598-018-26613-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
550 Gore AJ, Deitz SL, Palam LR, Craven KE, Korc M. Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation. J Clin Invest 2014;124:338-52. [PMID: 24334458 DOI: 10.1172/JCI71526] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
551 Lykoudis PM, Contis J. Estrogen Receptor Expression in Pancreatic Adenocarcinoma: Time to Reconsider Evidence. Pancreas 2021;50:1250-3. [PMID: 34860807 DOI: 10.1097/MPA.0000000000001921] [Reference Citation Analysis]
552 Park JK, Lee JH, Noh DH, Park JK, Lee KT, Lee JK, Lee KH, Jang KT, Cho J. Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma. Gut Liver 2020;14:387-94. [PMID: 31581388 DOI: 10.5009/gnl19011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
553 Winter JM, Tang LH, Klimstra DS, Liu W, Linkov I, Brennan MF, D’Angelica MI, DeMatteo RP, Fong Y, Jarnagin WR. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. Ann Surg. 2013;258:331-335. [PMID: 23360922 DOI: 10.1097/sla.0b013e31827fe9ce] [Cited by in Crossref: 51] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
554 Chin L, Hahn WC, Getz G, Meyerson M. Making sense of cancer genomic data. Genes Dev 2011;25:534-55. [PMID: 21406553 DOI: 10.1101/gad.2017311] [Cited by in Crossref: 226] [Cited by in F6Publishing: 191] [Article Influence: 20.5] [Reference Citation Analysis]
555 Cowan RW, Maitra A. Genetic progression of pancreatic cancer. Cancer J 2014;20:80-4. [PMID: 24445769 DOI: 10.1097/PPO.0000000000000011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
556 Wrzeszczynski KO, Rahman S, Frank MO, Arora K, Shah M, Geiger H, Felice V, Manaa D, Dikoglu E, Khaira D, Chimpiri AR, Michelini VV, Jobanputra V, Darnell RB, Powers S, Choi M. Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma. Cold Spring Harb Mol Case Stud 2019;5:a004424. [PMID: 31519698 DOI: 10.1101/mcs.a004424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
557 Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013;501:328-37. [PMID: 24048065 DOI: 10.1038/nature12624] [Cited by in Crossref: 1323] [Cited by in F6Publishing: 1202] [Article Influence: 147.0] [Reference Citation Analysis]
558 Ueda J, Tanaka M, Ohtsuka T, Tokunaga S, Shimosegawa T;  Research Committee of Intractable Diseases of the Pancreas. Surgery for chronic pancreatitis decreases the risk for pancreatic cancer: a multicenter retrospective analysis. Surgery. 2013;153:357-364. [PMID: 22989892 DOI: 10.1016/j.surg.2012.08.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
559 Bayraktar S, Rocha Lima CM. Emerging cell-cycle inhibitors for pancreatic cancer therapy. Expert Opinion on Emerging Drugs 2012;17:571-82. [DOI: 10.1517/14728214.2012.739606] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
560 Marchand B, Arsenault D, Raymond-Fleury A, Boisvert FM, Boucher MJ. Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells. J Biol Chem 2015;290:5592-605. [PMID: 25561726 DOI: 10.1074/jbc.M114.616714] [Cited by in Crossref: 106] [Cited by in F6Publishing: 67] [Article Influence: 15.1] [Reference Citation Analysis]
561 Yi JM, Guzzetta AA, Bailey VJ, Downing SR, Van Neste L, Chiappinelli KB, Keeley BP, Stark A, Herrera A, Wolfgang C. Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res. 2013;19:6544-6555. [PMID: 24088737 DOI: 10.1158/1078-0432.ccr-12-3224] [Cited by in Crossref: 84] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
562 Humeau M, Torrisani J, Cordelier P. miRNA in clinical practice: Pancreatic cancer. Clinical Biochemistry 2013;46:933-6. [DOI: 10.1016/j.clinbiochem.2013.03.019] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
563 Malhotra N, Jackson SA, Freed LL, Styn MA, Sidawy MK, Haddad NG, Finkelstein SD. The added value of using mutational profiling in addition to cytology in diagnosing aggressive pancreaticobiliary disease: review of clinical cases at a single center. BMC Gastroenterol 2014;14:135. [PMID: 25084836 DOI: 10.1186/1471-230X-14-135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
564 Philip PA. Novel targets for pancreatic cancer therapy. Surg Oncol Clin N Am 2010;19:419-29. [PMID: 20159523 DOI: 10.1016/j.soc.2009.11.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
565 Moravec R, Divi R, Verma M. Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World J Gastrointest Oncol 2017; 9(6): 235-250 [PMID: 28656074 DOI: 10.4251/wjgo.v9.i6.235] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
566 Willis JA, Olson SH, Orlow I, Mukherjee S, McWilliams RR, Kurtz RC, Klein RJ. A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival. Clin Cancer Res 2012;18:3942-51. [PMID: 22665904 DOI: 10.1158/1078-0432.CCR-11-2856] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
567 Olsen PA, Solberg NT, Lund K, Vehus T, Gelazauskaite M, Wilson SR, Krauss S. Implications of targeted genomic disruption of β-catenin in BxPC-3 pancreatic adenocarcinoma cells. PLoS One 2014;9:e115496. [PMID: 25536063 DOI: 10.1371/journal.pone.0115496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
568 Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends in Molecular Medicine 2013;19:428-46. [DOI: 10.1016/j.molmed.2013.04.005] [Cited by in Crossref: 164] [Cited by in F6Publishing: 174] [Article Influence: 18.2] [Reference Citation Analysis]
569 Verma M. The Role of Epigenomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools. Adv Exp Med Biol 2015;867:59-80. [PMID: 26530360 DOI: 10.1007/978-94-017-7215-0_5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
570 Basturk O, Hong SM, Wood LD, Adsay NV, Albores-Saavedra J, Biankin AV, Brosens LA, Fukushima N, Goggins M, Hruban RH, Kato Y, Klimstra DS, Klöppel G, Krasinskas A, Longnecker DS, Matthaei H, Offerhaus GJ, Shimizu M, Takaori K, Terris B, Yachida S, Esposito I, Furukawa T; Baltimore Consensus Meeting. A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol 2015;39:1730-41. [PMID: 26559377 DOI: 10.1097/PAS.0000000000000533] [Cited by in Crossref: 367] [Cited by in F6Publishing: 159] [Article Influence: 61.2] [Reference Citation Analysis]
571 Ismaili L, Romero A, Carreiras MDC, Marco-contelles J. Multitarget-Directed Antioxidants as Therapeutic Agents. Design of Hybrid Molecules for Drug Development. Elsevier; 2017. pp. 5-46. [DOI: 10.1016/b978-0-08-101011-2.00002-7] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
572 Yachida S, White CM, Naito Y, Zhong Y, Brosnan JA, Macgregor-Das AM, Morgan RA, Saunders T, Laheru DA, Herman JM. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res. 2012;18:6339-6347. [PMID: 22991414 DOI: 10.1158/1078-0432.ccr-12-1215] [Cited by in Crossref: 148] [Cited by in F6Publishing: 93] [Article Influence: 14.8] [Reference Citation Analysis]
573 Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt SM, Jessup JM. Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clin Cancer Res 2012;18:1515-23. [PMID: 22422403 DOI: 10.1158/1078-0432.CCR-11-2206] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
574 Zhang Y, Yan W, Mathew E, Kane KT, Brannon A 3rd, Adoumie M, Vinta A, Crawford HC, Pasca di Magliano M. Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice. Elife 2017;6:e27388. [PMID: 28980940 DOI: 10.7554/eLife.27388] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
575 Zeeh F, Witte D, Gädeken T, Rauch BH, Grage-Griebenow E, Leinung N, Fromm SJ, Stölting S, Mihara K, Kaufmann R, Settmacher U, Lehnert H, Hollenberg MD, Ungefroren H. Proteinase-activated receptor 2 promotes TGF-β-dependent cell motility in pancreatic cancer cells by sustaining expression of the TGF-β type I receptor ALK5. Oncotarget 2016;7:41095-109. [PMID: 27248167 DOI: 10.18632/oncotarget.9600] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
576 Neuzillet C, Hammel P, Tijeras-Raballand A, Couvelard A, Raymond E. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev. 2013;32:147-162. [PMID: 23085856 DOI: 10.1007/s10555-012-9396-2] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 7.7] [Reference Citation Analysis]
577 Quadri HS, Aiken TJ, Allgaeuer M, Moravec R, Altekruse S, Hussain SP, Miettinen MM, Hewitt SM, Rudloff U. Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer. BMC Cancer 2017;17:495. [PMID: 28732488 DOI: 10.1186/s12885-017-3481-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
578 Krieger TG, Le Blanc S, Jabs J, Ten FW, Ishaque N, Jechow K, Debnath O, Leonhardt CS, Giri A, Eils R, Strobel O, Conrad C. Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy. Nat Commun 2021;12:5826. [PMID: 34611171 DOI: 10.1038/s41467-021-26059-4] [Reference Citation Analysis]
579 Zhu X, Shen X, Qu J, Straubinger RM, Jusko WJ. Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. Front Pharmacol 2018;9:84. [PMID: 29520231 DOI: 10.3389/fphar.2018.00084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
580 Shao W, Hwang J, Liu C, Mukhopadhyay D, Zhao S, Shen MC, Selen ES, Wolfgang MJ, Farber SA, Espenshade PJ. Serum lipoprotein-derived fatty acids regulate hypoxia-inducible factor. J Biol Chem 2020;295:18284-300. [PMID: 33109611 DOI: 10.1074/jbc.RA120.015238] [Reference Citation Analysis]
581 Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, Hong SM, Zhao M, Rudek MA, Khan SR. A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Mol Cancer Ther. 2012;11:165-173. [PMID: 22027695 DOI: 10.1158/1535-7163.mct-11-0341] [Cited by in Crossref: 52] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
582 Thompson MJ, Rubbi L, Dawson DW, Donahue TR, Pellegrini M. Pancreatic cancer patient survival correlates with DNA methylation of pancreas development genes. PLoS One 2015;10:e0128814. [PMID: 26039411 DOI: 10.1371/journal.pone.0128814] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
583 Collisson EA, Cho RJ, Gray JW. What are we learning from the cancer genome? Nat Rev Clin Oncol 2012;9:621-30. [PMID: 22965149 DOI: 10.1038/nrclinonc.2012.159] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
584 Rustgi AK. A historical perspective on clinical advances in pancreatic diseases. Gastroenterology 2013;144:1249-51. [PMID: 23622134 DOI: 10.1053/j.gastro.2013.03.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
585 Wang ZX, Deng TX, Ma Z. Identification of a 4-miRNA signature as a potential prognostic biomarker for pancreatic adenocarcinoma. J Cell Biochem. 2019;120:16416-16426. [PMID: 31297864 DOI: 10.1002/jcb.28601] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
586 Roukos DH. Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 2010;10:247-50. [PMID: 20370580 DOI: 10.1586/erm.10.10] [Cited by in Crossref: 65] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
587 Ischenko I, Petrenko O, Hayman MJ. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells. Oncotarget 2015;6:15814-27. [PMID: 26158412 DOI: 10.18632/oncotarget.4538] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
588 Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA, McCue P, Knudsen ES. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget 2015;6:15788-801. [PMID: 26158861 DOI: 10.18632/oncotarget.3819] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
589 Zhang J, Shi K, Huang W, Weng W, Zhang Z, Guo Y, Deng T, Xiang Y, Ni X, Chen B, Zhou M. The DNA methylation profile of non-coding RNAs improves prognosis prediction for pancreatic adenocarcinoma. Cancer Cell Int 2019;19:107. [PMID: 31049029 DOI: 10.1186/s12935-019-0828-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
590 Meeker A, Heaphy C. Gastroenteropancreatic endocrine tumors. Molecular and Cellular Endocrinology 2014;386:101-20. [DOI: 10.1016/j.mce.2013.07.015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
591 Zhao X, Cao D, Ren Z, Liu Z, Lv S, Zhu J, Li L, Lang R, He Q. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma. Biosci Rep 2020;40:BSR20200214. [PMID: 32701143 DOI: 10.1042/BSR20200214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
592 Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G. State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol 2016; 8(1): 55-66 [PMID: 26798437 DOI: 10.4251/wjgo.v8.i1.55] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
593 Gu J, Taylor CR. Practicing pathology in the era of big data and personalized medicine. Appl Immunohistochem Mol Morphol 2014;22:1-9. [PMID: 24326463 DOI: 10.1097/PAI.0000000000000022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 3] [Article Influence: 3.4] [Reference Citation Analysis]
594 Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463:360-363. [PMID: 20054297 DOI: 10.1038/nature08672] [Cited by in Crossref: 841] [Cited by in F6Publishing: 794] [Article Influence: 70.1] [Reference Citation Analysis]
595 Cal S, López-Otín C. ADAMTS proteases and cancer. Matrix Biol 2015;44-46:77-85. [PMID: 25636539 DOI: 10.1016/j.matbio.2015.01.013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 9.0] [Reference Citation Analysis]
596 Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22. [PMID: 20579941 DOI: 10.1016/j.ccr.2010.05.026] [Cited by in Crossref: 2401] [Cited by in F6Publishing: 2253] [Article Influence: 200.1] [Reference Citation Analysis]
597 Brody JR, Dixon DA. Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 2018;9:e1469. [PMID: 29452455 DOI: 10.1002/wrna.1469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
598 Marx A, Alian A. The Road Less Traveled: HIV's Use of Alternative Routes through Cellular Pathways. J Virol 2015;89:5204-12. [PMID: 25762730 DOI: 10.1128/JVI.03684-14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
599 Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, Rao SS, Demuth T, Howat WJ, Jodrell DI. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med. 2012;209:437-444. [PMID: 22351932 DOI: 10.1084/jem.20111923] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 6.5] [Reference Citation Analysis]
600 Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:20723-20728. [PMID: 24297898 DOI: 10.1073/pnas.1314307110] [Cited by in Crossref: 163] [Cited by in F6Publishing: 152] [Article Influence: 18.1] [Reference Citation Analysis]
601 Herrera B, Inman GJ. A rapid and sensitive bioassay for the simultaneous measurement of multiple bone morphogenetic proteins. Identification and quantification of BMP4, BMP6 and BMP9 in bovine and human serum. BMC Cell Biol 2009;10:20. [PMID: 19298647 DOI: 10.1186/1471-2121-10-20] [Cited by in Crossref: 101] [Cited by in F6Publishing: 95] [Article Influence: 7.8] [Reference Citation Analysis]
602 Cencic R, Carrier M, Galicia-Vázquez G, Bordeleau ME, Sukarieh R, Bourdeau A, Brem B, Teodoro JG, Greger H, Tremblay ML, Porco JA Jr, Pelletier J. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One 2009;4:e5223. [PMID: 19401772 DOI: 10.1371/journal.pone.0005223] [Cited by in Crossref: 204] [Cited by in F6Publishing: 187] [Article Influence: 15.7] [Reference Citation Analysis]
603 Gayral M, Lulka H, Hanoun N, Biollay C, Sèlves J, Vignolle-Vidoni A, Berthommé H, Trempat P, Epstein AL, Buscail L, Béjot JL, Cordelier P. Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors. Hum Gene Ther 2015;26:104-13. [PMID: 25423447 DOI: 10.1089/hum.2014.072] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
604 Mishra NK, Guda C. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer. Oncotarget 2017;8:28990-9012. [PMID: 28423671 DOI: 10.18632/oncotarget.15993] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
605 Perales-Patón J, Piñeiro-Yañez E, Tejero H, López-Casas PP, Hidalgo M, Gómez-López G, Al-Shahrour F. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective. Public Health Genomics 2017;20:81-91. [PMID: 28858862 DOI: 10.1159/000479812] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
606 Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, Stuart W, McClaine R, Aronow B, Hoffman RM, Waltz SE, Lowy AM. Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res. 2010;70:1130-1140. [PMID: 20103639 DOI: 10.1158/0008-5472.can-09-0761] [Cited by in Crossref: 66] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
607 Sheahan AV, Biankin AV, Parish CR, Khachigian LM. Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. Oncotarget 2018;9:21613-27. [PMID: 29765563 DOI: 10.18632/oncotarget.25085] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
608 Chou A, Froio D, Nagrial AM, Parkin A, Murphy KJ, Chin VT, Wohl D, Steinmann A, Stark R, Drury A, Walters SN, Vennin C, Burgess A, Pinese M, Chantrill LA, Cowley MJ, Molloy TJ, Waddell N, Johns A, Grimmond SM, Chang DK, Biankin AV, Sansom OJ, Morton JP, Grey ST, Cox TR, Turchini J, Samra J, Clarke SJ, Timpson P, Gill AJ, Pajic M; Australian Pancreatic Cancer Genome Initiative (APGI). Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut 2018;67:2142-55. [PMID: 29080858 DOI: 10.1136/gutjnl-2017-315144] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 12.2] [Reference Citation Analysis]
609 Smith JP, Whitcomb DC, Matters GL, Brand RE, Liao J, Huang YJ, Frazier ML. Distribution of cholecystokinin-B receptor genotype between patients with pancreatic cancer and controls and its impact on survival. Pancreas 2015;44:236-42. [PMID: 25469546 DOI: 10.1097/MPA.0000000000000263] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
610 Feldmann G, Bisht S, Schütte U, Haarmann J, Brossart P. Everolimus for the treatment of pancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy 2012;13:2073-84. [DOI: 10.1517/14656566.2012.713348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
611 Chang X, Yu C, Li J, Yu S, Chen J. hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms. Int J Med Sci 2017;14:412-8. [PMID: 28539816 DOI: 10.7150/ijms.18641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
612 Westphalen CB, Olive KP. Genetically engineered mouse models of pancreatic cancer. Cancer J 2012;18:502-10. [PMID: 23187836 DOI: 10.1097/PPO.0b013e31827ab4c4] [Cited by in Crossref: 64] [Cited by in F6Publishing: 39] [Article Influence: 7.1] [Reference Citation Analysis]
613 Montagut C, Vidal J, Visa L. KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer. Annals of Oncology 2018;29:2280-2. [DOI: 10.1093/annonc/mdy484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
614 Wei P, Tang H, Li D. Insights into pancreatic cancer etiology from pathway analysis of genome-wide association study data. PLoS One. 2012;7:e46887. [PMID: 23056513 DOI: 10.1371/journal.pone.0046887] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
615 Price ND, Edelman LB, Lee I, Yoo H, Hwang D, Carlson G, Galas DJ, Heath JR, Hood L. Systems Biology and Systems Medicine. Essentials of Genomic and Personalized Medicine. Elsevier; 2010. pp. 131-41. [DOI: 10.1016/b978-0-12-374934-5.00011-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
616 Ravi D, Wiles AM, Bhavani S, Ruan J, Leder P, Bishop AJ. A network of conserved damage survival pathways revealed by a genomic RNAi screen. PLoS Genet 2009;5:e1000527. [PMID: 19543366 DOI: 10.1371/journal.pgen.1000527] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
617 Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther. 2013;7:33-43. [PMID: 24379681 DOI: 10.2147/ott.s38111] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
618 Baer R, Cintas C, Dufresne M, Cassant-Sourdy S, Schönhuber N, Planque L, Lulka H, Couderc B, Bousquet C, Garmy-Susini B. Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α. Genes Dev. 2014;28:2621-2635. [PMID: 25452273 DOI: 10.1101/gad.249409.114] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 10.9] [Reference Citation Analysis]
619 Takai E, Totoki Y, Nakamura H, Kato M, Shibata T, Yachida S. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer. Adv Exp Med Biol 2016;924:13-7. [PMID: 27753011 DOI: 10.1007/978-3-319-42044-8_3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
620 Zhao J, Lee SH, Huss M, Holme P. The network organization of cancer-associated protein complexes in human tissues. Sci Rep 2013;3:1583. [PMID: 23567845 DOI: 10.1038/srep01583] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
621 Huang C, Du J, Xie K. FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis. Biochim Biophys Acta 2014;1845:104-16. [PMID: 24418574 DOI: 10.1016/j.bbcan.2014.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
622 Whitcomb DC, Shelton CA, Brand RE. Genetics and Genetic Testing in Pancreatic Cancer. Gastroenterology. 2015;149:1252-1264.e4. [PMID: 26255042 DOI: 10.1053/j.gastro.2015.07.057] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
623 Check Hayden E. Cancer complexity slows quest for cure. Nature 2008;455:148. [PMID: 18784686 DOI: 10.1038/455148a] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
624 Valero V 3rd, Saunders TJ, He J, Weiss MJ, Cameron JL, Dholakia A, Wild AT, Shin EJ, Khashab MA, O'Broin-Lennon AM, Ali SZ, Laheru D, Hruban RH, Iacobuzio-Donahue CA, Herman JM, Wolfgang CL. Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. Ann Surg 2016;263:153-61. [PMID: 26020105 DOI: 10.1097/SLA.0000000000001156] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
625 Malgerud L, Lindberg J, Wirta V, Gustafsson-Liljefors M, Karimi M, Moro CF, Stecker K, Picker A, Huelsewig C, Stein M, Bohnert R, Del Chiaro M, Haas SL, Heuchel RL, Permert J, Maeurer MJ, Brock S, Verbeke CS, Engstrand L, Jackson DB, Grönberg H, Löhr JM. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Mol Oncol 2017;11:1413-29. [PMID: 28675654 DOI: 10.1002/1878-0261.12108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
626 de Wilde RF, Hruban RH, Maitra A, Offerhaus GJA. Reporting precursors to invasive pancreatic cancer: pancreatic intraepithelial neoplasia, intraductal neoplasms and mucinous cystic neoplasm. Diagnostic Histopathology 2012;18:17-30. [DOI: 10.1016/j.mpdhp.2011.10.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
627 Kulawiec M, Salk JJ, Ericson NG, Wanagat J, Bielas JH. Generation, function, and prognostic utility of somatic mitochondrial DNA mutations in cancer. Environ Mol Mutagen 2010;51:427-39. [PMID: 20544883 DOI: 10.1002/em.20582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
628 Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, Sarkar FH, Mohammad RM. Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget 2011;2:378-92. [PMID: 21623005 DOI: 10.18632/oncotarget.269] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
629 Han B, Qu C, Park K, Konieczny SF, Korc M. Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip. Cancer Lett 2016;380:319-29. [PMID: 26688098 DOI: 10.1016/j.canlet.2015.12.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
630 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 849] [Article Influence: 125.2] [Reference Citation Analysis]
631 Zhou B, Wu Q, Chen G, Zhang T, Zhao Y. NOP14 promotes proliferation and metastasis of pancreatic cancer cells. Cancer Letters 2012;322:195-203. [DOI: 10.1016/j.canlet.2012.03.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
632 Ren B, Liu X, Suriawinata AA. Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: Histopathology, Cytopathology, and Molecular Pathology. Am J Pathol. 2019;189:9-21. [PMID: 30558727 DOI: 10.1016/j.ajpath.2018.10.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
633 Warenius HM. Technological challenges of theranostics in oncology. Expert Opinion on Medical Diagnostics 2009;3:381-93. [DOI: 10.1517/17530050902893295] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
634 Demeure MJ, Craig DW, Sinari S, Moses TM, Christoforides A, Dinh J, Izatt T, Aldrich J, Decker A, Baker A. Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerability. Genome Med. 2012;4:56. [PMID: 22762308 DOI: 10.1186/gm357] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
635 Dosch JS, Ziemke EK, Shettigar A, Rehemtulla A, Sebolt-Leopold JS. Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer. Cancer Res 2015;75:4582-92. [PMID: 26359451 DOI: 10.1158/0008-5472.CAN-14-2793] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
636 Adams CR, Htwe HH, Marsh T, Wang AL, Montoya ML, Subbaraj L, Tward AD, Bardeesy N, Perera RM. Transcriptional control of subtype switching ensures adaptation and growth of pancreatic cancer. Elife 2019;8:e45313. [PMID: 31134896 DOI: 10.7554/eLife.45313] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 9.7] [Reference Citation Analysis]
637 Khalil I, Brewer MA, Neyarapally T, Runowicz CD. The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer. Gynecol Oncol 2010;116:282-5. [PMID: 19931138 DOI: 10.1016/j.ygyno.2009.10.085] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
638 Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF-kappaB signaling. J Mol Cell Biol 2011;3:159-66. [PMID: 21502305 DOI: 10.1093/jmcb/mjr007] [Cited by in Crossref: 405] [Cited by in F6Publishing: 398] [Article Influence: 36.8] [Reference Citation Analysis]
639 Apken LH, Oeckinghaus A. The RAL signaling network: Cancer and beyond. Int Rev Cell Mol Biol 2021;361:21-105. [PMID: 34074494 DOI: 10.1016/bs.ircmb.2020.10.005] [Reference Citation Analysis]
640 Aggarwal BB, Danda D, Gupta S, Gehlot P. Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol. 2009;78:1083-1094. [PMID: 19481061 DOI: 10.1016/j.bcp.2009.05.027] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 7.3] [Reference Citation Analysis]
641 Deharvengt S, Marmarelis M, Korc M. Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer. PLoS One 2012;7:e39684. [PMID: 22761868 DOI: 10.1371/journal.pone.0039684] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
642 Barreto SG. Pancreatic Cancer. In: Barreto SG, Windsor JA, editors. Surgical Diseases of the Pancreas and Biliary Tree. Singapore: Springer; 2018. pp. 427-69. [DOI: 10.1007/978-981-10-8755-4_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
643 Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, Nomoto K, Pollock PM. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 2012;11:75. [PMID: 23039341 DOI: 10.1186/1476-4598-11-75] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
644 Torres C, Grippo PJ. Pancreatic cancer subtypes: a roadmap for precision medicine. Ann Med 2018;50:277-87. [PMID: 29537309 DOI: 10.1080/07853890.2018.1453168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
645 Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer 2011;11:450-7. [PMID: 21593786 DOI: 10.1038/nrc3063] [Cited by in Crossref: 263] [Cited by in F6Publishing: 225] [Article Influence: 23.9] [Reference Citation Analysis]
646 Bijlsma MF, van Laarhoven HW. The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. Cancer Metastasis Rev 2015;34:97-114. [PMID: 25566685 DOI: 10.1007/s10555-014-9541-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
647 Jones M, Zheng Z, Wang J, Dudley J, Albanese E, Kadayifci A, Dias-Santagata D, Le L, Brugge WR, Fernandez-del Castillo C, Mino-Kenudson M, Iafrate AJ, Pitman MB. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. Gastrointest Endosc 2016;83:140-8. [PMID: 26253016 DOI: 10.1016/j.gie.2015.06.047] [Cited by in Crossref: 88] [Cited by in F6Publishing: 71] [Article Influence: 12.6] [Reference Citation Analysis]
648 Zhang Y, Morris JP, Yan W, Schofield HK, Gurney A, Simeone DM, Millar SE, Hoey T, Hebrok M, Pasca di Magliano M. Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res. 2013;73:4909-4922. [PMID: 23761328 DOI: 10.1158/0008-5472.can-12-4384] [Cited by in Crossref: 121] [Cited by in F6Publishing: 84] [Article Influence: 13.4] [Reference Citation Analysis]
649 Pietrobono S, Stecca B. Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors. Cells 2018;7:E272. [PMID: 30558232 DOI: 10.3390/cells7120272] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
650 Gong H, Wu TT, Clarke EM. Pathway-gene identification for pancreatic cancer survival via doubly regularized Cox regression. BMC Syst Biol 2014;8 Suppl 1:S3. [PMID: 24565114 DOI: 10.1186/1752-0509-8-S1-S3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
651 McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Hum Vaccin Immunother 2016;12:563-75. [PMID: 26619245 DOI: 10.1080/21645515.2015.1093264] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
652 Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, Vogelstein B, Karchin R. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res 2009;69:6660-7. [PMID: 19654296 DOI: 10.1158/0008-5472.CAN-09-1133] [Cited by in Crossref: 323] [Cited by in F6Publishing: 215] [Article Influence: 24.8] [Reference Citation Analysis]
653 Qendro V, Lundgren DH, Palczewski S, Hegde P, Stevenson C, Perpetua L, Latifi A, Merriman J, Bugos G, Han DK. Discovery of putative breast cancer antigens using an integrative platform of genomics-driven immunoproteomics. Proteomics 2017;17. [PMID: 28665052 DOI: 10.1002/pmic.201600318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
654 Elgogary A, Xu Q, Poore B, Alt J, Zimmermann SC, Zhao L, Fu J, Chen B, Xia S, Liu Y, Neisser M, Nguyen C, Lee R, Park JK, Reyes J, Hartung T, Rojas C, Rais R, Tsukamoto T, Semenza GL, Hanes J, Slusher BS, Le A. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A 2016;113:E5328-36. [PMID: 27559084 DOI: 10.1073/pnas.1611406113] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 19.7] [Reference Citation Analysis]
655 Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338-350. [PMID: 22508028 DOI: 10.1038/nrclinonc.2012.61] [Cited by in Crossref: 773] [Cited by in F6Publishing: 699] [Article Influence: 77.3] [Reference Citation Analysis]
656 Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, Borges M, Goggins M. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010;70:5226-37. [PMID: 20551052 DOI: 10.1158/0008-5472.CAN-09-4227] [Cited by in Crossref: 203] [Cited by in F6Publishing: 137] [Article Influence: 16.9] [Reference Citation Analysis]
657 Conner JR, Mariño-enríquez A, Mino-kenudson M, Garcia E, Pitman MB, Sholl LM, Srivastava A, Doyle LA. Genomic Characterization of Low- and High-Grade Pancreatic Mucinous Cystic Neoplasms Reveals Recurrent KRAS Alterations in “High-Risk” Lesions. Pancreas 2017;46:665-71. [DOI: 10.1097/mpa.0000000000000805] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 3.2] [Reference Citation Analysis]
658 Yadav DK, Bai X, Yadav RK, Singh A, Li G, Ma T, Chen W, Liang T. Liquid biopsy in pancreatic cancer: the beginning of a new era. Oncotarget 2018;9:26900-33. [PMID: 29928492 DOI: 10.18632/oncotarget.24809] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
659 Safe S, Shrestha R, Mohankumar K, Howard M, Hedrick E, Abdelrahim M. Transcription factors specificity protein and nuclear receptor 4A1 in pancreatic cancer. World J Gastroenterol 2021; 27(38): 6387-6398 [PMID: 34720529 DOI: 10.3748/wjg.v27.i38.6387] [Reference Citation Analysis]
660 Karunasena E, Sham J, McMahon KW, Ahuja N. Genomics of Peritoneal Malignancies. Surg Oncol Clin N Am 2018;27:463-75. [PMID: 29935683 DOI: 10.1016/j.soc.2018.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
661 Lee B, Hutchinson R, Wong HL, Tie J, Putoczki T, Tran B, Gibbs P, Christie M. Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. Semin Cancer Biol. 2018;52:241-252. [PMID: 29258858 DOI: 10.1016/j.semcancer.2017.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
662 Zakharenko AL, Lebedeva NA, Lavrik OI. DNA Repair Enzymes as Promising Targets in Oncotherapy. Russ J Bioorg Chem 2018;44:1-18. [DOI: 10.1134/s1068162017060140] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
663 Garrett SH, Somji S, Sens DA, Zhang KK. Prediction of the number of activated genes in multiple independent Cd(+2)- and As(+3)-induced malignant transformations of human urothelial cells (UROtsa). PLoS One 2014;9:e85614. [PMID: 24465620 DOI: 10.1371/journal.pone.0085614] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
664 Bi HC, Pan YZ, Qiu JX, Krausz KW, Li F, Johnson CH, Jiang CT, Gonzalez FJ, Yu AM. N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. Carcinogenesis 2014;35:2264-72. [PMID: 25115443 DOI: 10.1093/carcin/bgu174] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
665 Samulitis BK, Pond KW, Pond E, Cress AE, Patel H, Wisner L, Patel C, Dorr RT, Landowski TH. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 2015;16:43-51. [PMID: 25485960 DOI: 10.4161/15384047.2014.986967] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
666 Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJ. Molecular characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int. 2011;2011:620601. [PMID: 21512581 DOI: 10.4061/2011/620601] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
667 González-Titos A, Hernández-Camarero P, Barungi S, Marchal JA, Kenyon J, Perán M. Trypsinogen and chymotrypsinogen: potent anti-tumor agents. Expert Opin Biol Ther 2021;:1-13. [PMID: 33896307 DOI: 10.1080/14712598.2021.1922666] [Reference Citation Analysis]
668 Seldon CS, Colbert LE, Hall WA, Fisher SB, Yu DS, Landry JC. Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas. World J Gastrointest Oncol 2016; 8(4): 358-365 [PMID: 27096031 DOI: 10.4251/wjgo.v8.i4.358] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
669 Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805:105-117. [PMID: 19931353 DOI: 10.1016/j.bbcan.2009.11.002] [Cited by in Crossref: 377] [Cited by in F6Publishing: 639] [Article Influence: 29.0] [Reference Citation Analysis]
670 Kong B, Wang W, Esposito I, Friess H, Michalski CW, Kleeff J. Increased expression of Nodal correlates with reduced patient survival in pancreatic cancer. Pancreatology 2015;15:156-61. [PMID: 25708930 DOI: 10.1016/j.pan.2015.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
671 Omura N, Mizuma M, MacGregor A, Hong SM, Ayars M, Almario JA, Borges M, Kanda M, Li A, Vincent A, Maitra A, Goggins M. Overexpression of ankyrin1 promotes pancreatic cancer cell growth. Oncotarget 2016;7:34977-87. [PMID: 27144336 DOI: 10.18632/oncotarget.9009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3]